[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1551
1. Saglam A, Can B: Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman. J Clin Pathol; 2005 Jan;58(1):87-9
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman.
  • Histopathological examination of the mastectomy specimen revealed a high grade infiltrating ductal adenocarcinoma intermixed with a lactating adenoma.
  • Lactating adenomas are rare entities but are the most common masses that occur during pregnancy.
  • Although they are not thought to carry an increased risk of cancer there are two other case reports in the literature of a lactating adenoma associated with an infiltrating carcinoma.
  • In this case, areas where the lactating adenoma and the infiltrating carcinoma were intermixed could be identified.
  • This case could simply be a collision tumour, although the possibility of an invasive carcinoma arising within a lactating adenoma cannot be ruled out.
  • Because of the relative lack of experience with lactating adenomas, the question of an increased association with carcinoma development remains unclear.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neoplasms, Multiple Primary / pathology. Pregnancy Complications, Neoplastic / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] Cancer. 1954 Mar;7(2):318-24 [13141224.001]
  • [Cites] Pathol Int. 2002 Mar;52(3):244-8 [11972869.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 3:iii31-6 [12821536.001]
  • [Cites] Virchows Arch. 2003 Jul;443(1):44-50 [12756565.001]
  • [Cites] Cancer. 1976 Jun;37(6):2891-905 [949710.001]
  • [Cites] Lancet. 1989 Feb 4;1(8632):252 [2563418.001]
  • [Cites] Acta Cytol. 1990 Jan-Feb;34(1):21-6 [2153326.001]
  • [Cites] Histopathology. 1993 May;22(5):481-5 [8344658.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1220-8 [8826943.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2744-51 [9389738.001]
  • [Cites] Pharmacol Ther. 1998 Aug;79(2):169-78 [9749881.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Apr;13(2):311-32 [10363133.001]
  • [Cites] Endocr Relat Cancer. 1999 Sep;6(3):389-404 [10516853.001]
  • [Cites] Breast J. 2001 Sep-Oct;7(5):354-7 [11906446.001]
  • (PMID = 15623491.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770558
  •  go-up   go-down


2. Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, Nomoto K, Takano Y: An immunohistochemical study of P53 and Ki-67 in gastrointestinal adenoma and adenocarcinoma using tissue microarray. Anticancer Res; 2006 May-Jun;26(3B):2353-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of P53 and Ki-67 in gastrointestinal adenoma and adenocarcinoma using tissue microarray.
  • BACKGROUND: Gastrointestinal carcinogenesis generally follows the adenoma-adenocarcinoma sequence and tumor metastasis determines the survival time of the patients.
  • The expressions of p53 and ki-67 in gastrointestinal adenoma and adenocarcinoma (GIA) were explored and their clinicopathological significance determined.
  • MATERIALS AND METHODS: The expressions of mutant p53 and ki-67 were examined on tissue microarray containing GIA, adjacent mucosa or adenoma and metastases by immunostaining.
  • RESULTS: The expressions of mutant p53 and ki-67 were gradually increased from gastrointestinal mucosa to adenocarcinoma through adenoma (p<0.05).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Gastrointestinal Neoplasms / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821616.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


3. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer; 2005 Jan 10;113(2):198-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
  • In all of 24 cases of colorectal adenocarcinoma TIMP-1 mRNA was detected by in situ hybridization.
  • TIMP-1 mRNA was detected in 2 of 7 adenomatous polyps in the adenoma area: in both cases associated with focal stromal inflammation at the epithelial-stromal interface.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


Advertisement
4. Ma Q, Wang Y, Gao X, Ma Z, Song Z: L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin Cancer Res; 2007 Dec 15;13(24):7407-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma.
  • PURPOSE: Evidence suggests that the majority of colorectal carcinomas arise from adenomas, and L-arginine suppresses colorectal tumorigenesis.
  • We suppose that L-arginine may inhibit the process of carcinogenesis from colorectal adenoma to adenocarcinoma.
  • EXPERIMENTAL DESIGN: We selected 60 patients with colorectal cancer and 60 patients with colorectal adenoma (CRA) and divided them into four groups of 30 patients each.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / drug therapy. Arginine / therapeutic use. Colorectal Neoplasms / drug therapy. Ornithine Decarboxylase / drug effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094424.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 31C4KY9ESH / Nitric Oxide; 94ZLA3W45F / Arginine; EC 1.14.13.39 / Nitric Oxide Synthase; EC 4.1.1.17 / Ornithine Decarboxylase
  •  go-up   go-down


5. Guan J, Chen J, Luo YF, Cao JL, Zhao H, Hao J: [Expression of survivin in colorectal adenoma and adenocarcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Jun;29(3):398-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin in colorectal adenoma and adenocarcinoma].
  • METHODS Immunohistochemistry staining was performed by two-step EnVision technique for the paraffin sections, which included 90 adenomas, 25 ademomas with high-grade glandular intraepithelial neoplasia, and 108 colorectal adenocarcinomas.
  • The positive rate of SVV in tubular adenomas, villous adenomas, and tubulovillous adenomas were 30% (12/40), 40.9% (9/22), and 35.8% (10/28), respectively.
  • The positive rate of SVV in tubulovillous adenomas with high-grade glandular intraepithelial neoplasia were 68% (17/25).
  • SVV expressions among the three types of adenomas without neoplasia were not significantly different (P > 0.05).
  • SVV expression between each type of the above-mentioned ademoma and tubulovillous adenoma with high-grade glandular intraepithelial neoplasia or different Dukes stages of colorectal carcinoma was significantly different (P < 0.05).
  • SVV expressions in adenocarcinomas and adenomas with high grade glandular intraepithelial neoplasia were significantly higher than those in adenomas (P < 0.01).
  • SVV expression may be useful to distinguish adenocarcinoma from adenoma in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Microtubule-Associated Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633470.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


6. Tarakji B, Nassani MZ: Immunohistochemical expression of p21 in normal tissues of salivary gland, pleomorphic adenoma and carcinoma ex pleomorphic adenoma-(undifferentiated and adenocarcinoma types). Med Oral Patol Oral Cir Bucal; 2010 Sep;15(5):e697-703
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p21 in normal tissues of salivary gland, pleomorphic adenoma and carcinoma ex pleomorphic adenoma-(undifferentiated and adenocarcinoma types).
  • OBJECTIVE: Our study aimed to characterize alteration in the immunohistochemical expression of p21 in normal tissue of the salivary gland surrounding pleomorphic adenoma, the tumor cells of pleomorphic adenomas, and carcinoma arising in pleomorphic adenoma.
  • STUDY DESIGN: A selected series of 29 cases of pleomorphic adenomas, and 27 cases of carcinoma ex-pleomorphic adenoma (undifferentiated and adenocarcinoma types) were examined.
  • RESULTS: The results showed that p21 expression was negative in the most components of normal tissue of the salivary gland surrounding pleomorphic adenoma, 24 cases out of 29 of the non tumour duct cells (82.8%), and 28 (96.6%) cases out of 29 of the acinar cells shows negative p21 expression.
  • P21 expression in pleomorphic adenomas shows that 2 cases out of 29 (6.9%) strongly expressed in the duct cells. p21 was strongly expressed in carcinoma cells in 9 (33.3%) cases out of 27.
  • CONCLUSION: Our data suggest that the strong nuclear staining as an indicator for altered p21, then the alteration of p21 expression would increase from pleomorphic adenoma to carcinoma arising in pleomorphic adenomas (6.9% versus 33.3%).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis. Salivary Gland Neoplasms / metabolism. Salivary Glands / metabolism

  • Genetic Alliance. consumer health - Salivary gland adenoma, pleomorphic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20383106.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21
  •  go-up   go-down


7. Tarakji B, Kujan O, Nassani MZ: Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma. J Cancer Epidemiol; 2010;2010:250606
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma.
  • This marker may be useful in differentiating pleomorphic adenoma (PA) from carcinoma ex pleomorphic adenoma (CPA), as these tumors are often difficult to distinguish on the basis of morphology alone.
  • Design. Paraffin blocks of 29 cases of PA, which were surrounded by normal parotid gland, and 27 cases of carcinoma ex pleomorphic adenoma were retrieved and validated.
  • In all cases of carcinoma ex pleomorphic adenoma, a PA "ghost" was identified, and the malignant element was either undifferentiated carcinoma or adenocarcinoma.
  • Nuclear P53 was expressed strongly in 6/29 (20.7%) pleomorphic salivary adenoma and 10/27 (37%) carcinoma ex pleomorphic adenoma.
  • Conclusion. Our data suggest that inactivation of p53 may play an important role in the evolution of pleomorphic salivary adenoma and carcinoma ex pleomorphic adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Jun;182(2):180-4 [9274528.001]
  • [Cites] Pathol Int. 1998 Apr;48(4):265-72 [9648154.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):477-83 [10675478.001]
  • [Cites] Cancer Lett. 1992 Jul 31;65(1):61-71 [1324786.001]
  • [Cites] J Immunol Methods. 1992 Jul 6;151(1-2):237-44 [1378473.001]
  • [Cites] J Pathol. 1992 Apr;166(4):389-94 [1381431.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2008 Sep-Oct;12(5):321-5 [19024217.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):413-22 [8396843.001]
  • [Cites] Br J Cancer. 1996 Mar;73(6):728-34 [8611372.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):224-31 [9917133.001]
  • [Cites] Hum Pathol. 2009 Mar;40(3):390-7 [18992915.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):113-21 [6263450.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2037-44 [7697591.001]
  • [Cites] Hum Pathol. 1996 Aug;27(8):782-6 [8760010.001]
  • [Cites] J Oral Pathol Med. 1997 May;26(5):217-23 [9178173.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2314-9 [9191518.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):539-45 [10203588.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Aug;21(4):336-42 [10560511.001]
  • (PMID = 21253477.001).
  • [ISSN] 1687-8566
  • [Journal-full-title] Journal of cancer epidemiology
  • [ISO-abbreviation] J Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3022193
  •  go-up   go-down


8. Holten-Andersen MN, Brunner N, Nielsen HJ, Christensen IJ, Moller Sorensen N, Schrol Rasmussen AS, Primdahl H, Orntoft T: Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer. Int J Biol Markers; 2006 Jan - Mar;21(1):6-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: TIMP-1 levels were determined in urine and plasma from healthy donors (n=26), patients with bacterial bladder infection (n=24), urothelial bladder adenoma (n=3) or adenocarcinoma (n=7).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207096.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Kang WY, Chen WT, Wu MT, Chai CY: The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int J Colorectal Dis; 2007 Aug;22(8):869-74
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma.
  • BACKGROUND: The aim of our study was to analyze the expression and possible role of CD66a in colorectal adenoma and adenocarcinoma and the relationship between its expression and pre-operation serum carcinoembryonic antigen (CEA) level and tumor stage in patients with colorectal adenocarcinomas.
  • METHODS: Paraffin-embedded sections from 184 patients including 42 colorectal adenomas with low-grade dysplasia, 43 adenomas with high-grade dysplasia, and 99 adenocarcinomas were collected for this study.
  • RESULTS: The expression of CD66a was found not only in the apical membrane of neoplastic glands but also in secretion within the lumen of the neoplastic glands including adenomas and adenocarcinomas.
  • Expressions of secreted CD66a were of higher level in adenocarcinoma than in adenoma with high-grade dysplasia and adenoma with low-grade dysplasia (p < 0.0001).
  • High expression of secreted CD66a was also associated with tumor stage, invasion, and pre-operation serum CEA level of patients with colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Adenoma / immunology. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Colorectal Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1236-44 [10728682.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] J Histochem Cytochem. 1988 Jul;36(7):729-39 [3290331.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1273-84 [11884526.001]
  • [Cites] Cancer Gene Ther. 1999 Jul-Aug;6(4):313-21 [10419049.001]
  • [Cites] J Cell Biol. 1992 Jul;118(2):457-66 [1378450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10744-8 [7504281.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 23;227(3):775-81 [8886009.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):250-7 [8317550.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):849-56 [8088758.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17894-9 [10749878.001]
  • [Cites] Eur J Biochem. 1993 May 1;213(3):1109-16 [8504806.001]
  • [Cites] J Histochem Cytochem. 1996 Jan;44(1):35-41 [8543780.001]
  • [Cites] J Immunol. 1993 Jun 1;150(11):4978-84 [8496599.001]
  • [Cites] Br J Cancer. 1998 May;77(10):1661-8 [9635845.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6959-63 [2457922.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1401-6 [9626043.001]
  • [Cites] Mol Immunol. 1979 Apr;16(4):245-52 [91094.001]
  • [Cites] J Histochem Cytochem. 1997 Jul;45(7):957-63 [9212821.001]
  • (PMID = 17143599.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CTNNB1 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / beta Catenin
  •  go-up   go-down


10. Bakaris S, Cetinkaya A, Ezberci F, Ekerbicer H: Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma. Histol Histopathol; 2008 09;23(9):1043-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.
  • When compared to the intensity observed in adjacent normal mucosal epithelial cells, strong nuclear staining for CDX2 was observed in 10 (100%) of 10 colonic adenomas, 30 (88.2%) of 34 colorectal adenocarcinomas, including 17(94.47%) of 18 well-or moderately differentiated tumors and 13(81.2%) of 16 high-grade tumors.
  • The percentage of CDX2 immunopositive cells was generally lower in carcinomas than in adenomas (p<0.001) and lower in moderately or poorly differentiated tumors than in well-differentiated tumors (p<0.001).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Homeodomain Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581275.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


11. Fukuyama M, Rokutan K, Sano T, Miyake H, Shimada M, Tashiro S: Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon. Cancer Lett; 2005 Apr 18;221(1):97-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon.
  • Adenomas and well differentiated adenocarcinomas up-regulated Nox1 expression.
  • Nuclear factor (NF)-kappaB was predominantly activated in adenoma and adenocarcinoma cells expressing abundant Nox1, suggesting that Nox1 may stimulate NF-kappaB-dependent antiapoptotic pathways in colon tumors.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Colonic Neoplasms / enzymology. NADPH Oxidase / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797632.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / NF-kappa B; EC 1.6.3.- / NOX1 protein, human; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


12. Tong GX, Weeden EM, Hamele-Bena D, Huan Y, Unger P, Memeo L, O'Toole K: Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol; 2008 Sep;32(9):1380-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
  • Recent evidence has showed that nephrogenic adenoma is a true "nephrogenic" lesion derived from the proliferation of exfoliated and implanted renal tubular cells in the urinary tract, a process that closely resembles the formation of endometriosis.
  • This new concept has led to the identification of renal transcription factor PAX2 as a diagnostic marker for nephrogenic adenoma.
  • In this study, we investigated the expression of PAX8 in nephrogenic adenoma and its mimics.
  • We report here that PAX8 was detected in all nephrogenic adenomas (N=35) and clear cell adenocarcinoma of the lower urinary tract (N=7), but not in prostate adenocarcinoma (N=100), adenocarcinoma (N=9), squamous cell carcinoma (N=5), or urothelial carcinoma (N=48) of the urinary bladder and its variants.
  • PAX2 was also detected in 2 of the 7 clear cell adenocarcinomas of the lower urinary tract.
  • We suggest that PAX8 is an additional marker for identifying nephrogenic adenoma.
  • Expression of PAX8 or PAX2 in both nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract may indicate a possible related tissue origin for these 2 lesions; both may be derived from proliferating renal tubular cells in the urinary tract.
  • In addition, detection of PAX8 or PAX2 in clear cell adenocarcinoma of the lower urinary tract is helpful in differentiating it from urothelial carcinoma and its variants and adenocarcinomas of the urinary bladder or of the prostate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenoma / metabolism. Biomarkers, Tumor / analysis. Paired Box Transcription Factors / biosynthesis. Urologic Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670350.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


13. Wang Y, Zhou ZG, Xia QJ, Zhang WY, Li HG, Wang R: [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):465-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance].
  • OBJECTIVE: To investigate the expression differences of minichromosome maintenance 2 (MCM2) mRNA and protein among colon adenocarcinoma, colon adenoma and normal mucosa, and among different clinicopathological types of adenomas.
  • METHODS: Fifty specimens, including 33 colonic adenomas, 12 colonic adenocarcinomas and 5 normal colonic mucosa were selected.
  • Expression differences of MCM2 mRNA among the colonic adenocarcinoma, adenoma and normal colonic mucosa were evaluated by REST-XL software.
  • RESULTS: The expression of MCM2 was observed in the basal third to half of the colonic crypts in normal mucosa, while throughout the epithelium in the colonic adenocarcinomas and adenomas.
  • However, the expression of MCM2 mRNA in the adenocarcinomas was significantly higher than that in the adenomas(P=0.001).
  • The MCM2 mRNA expression was elevated in the adenoma with villous type, in the conditions of high-grade dysplasia, larger size, sessile morphology and in patients of older ages, but the difference was not significant by REST-XL (P>0.05).
  • CONCLUSION: The difference of MCM2 expression between the adenoma and the adenocarcinoma indicates its potential value in the early diagnosis of colonic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Cycle Proteins / metabolism. Colonic Neoplasms / metabolism. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803052.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


14. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


15. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


16. Calistri D, Rengucci C, Casadei-Gardini A, Scarpi E, Zoli W, Falcini F, Milandri C, Amadori D, Silvestrini R: FL-DNA approach for noninvasive early diagnosis of colorectal cancer in FOBT-screened patients. J Clin Oncol; 2009 May 20;27(15_suppl):11062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 560 individuals with FOBT-positive stool subjected to colonoscopy, 26 were diagnosed with adenocarcinoma, 264 with high-grade adenoma and 54 with low-grade adenoma.
  • RESULTS: Using a cut-off of 10 ng, the molecular analysis detected over 90% of the colorectal cancers and about 50% of the high- and low-grade adenomas.
  • A more in depth DNA stool evaluation in negative FOBT individuals could reveal the test's usefulness in unmasking colorectal tumors and adenomas missed by FOBT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kim HO, Hwang SI, Yoo CH, Kim H: Preoperative colonoscopy for patients with gastric adenocarcinoma. J Gastroenterol Hepatol; 2009 Nov;24(11):1740-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative colonoscopy for patients with gastric adenocarcinoma.
  • BACKGROUND AND AIM: In patients with gastric adenocarcinoma (GA), the most common double primary cancer is colorectal cancer.
  • The prevalence of colorectal neoplasms (CRN, adenoma and adenocarcinoma) was evaluated according to age, sex, body mass index (BMI) and stage, location and differentiation of GA.
  • Synchronous adenoma and adenocarcinoma were detected in 68 (33.2%) and four (2.0%) patients, respectively.
  • All of the GA patients with synchronous colorectal adenocarcinoma were older than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonoscopy. Colorectal Neoplasms / pathology. Gastrectomy. Mass Screening / methods. Neoplasms, Second Primary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Databases as Topic. Female. Humans. Incidence. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Predictive Value of Tests. Preoperative Care. Prevalence. Risk Assessment. Risk Factors


18. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


19. Habermann N, Schön A, Lund EK, Glei M: Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. Apoptosis; 2010 May;15(5):621-30
MedlinePlus Health Information. consumer health - Dietary Fats.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo.
  • LT97 human colon adenoma and HT29 human colon adenocarcinoma cells were used to investigate modulation of apoptosis by EPA, DHA or linoleic acid (LA) using a set of endpoints, namely phosphatidylserine staining with Annexin-V (flow cytometry), Bcl-2 expression (Real-time RT-PCR), and Bid, caspase 3, 8 and 9 expression as well as PARP cleavage (Western Blot).
  • Taken together, our results show that adenoma cells are highly susceptible to n-3 PUFA-induced apoptosis.
  • [MeSH-major] Adenocarcinoma. Apoptosis / drug effects. Biomarkers / metabolism. Colorectal Neoplasms. Dietary Fats. Fatty Acids, Omega-3. Fishes

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20107900.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BH3 Interacting Domain Death Agonist Protein; 0 / Biomarkers; 0 / Caspase Inhibitors; 0 / Dietary Fats; 0 / Fatty Acids, Omega-3; 0 / Fish Oils; 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases
  •  go-up   go-down


20. Ishida M, Hotta M, Kushima R, Tsuruoka S, Ohji M, Okabe H: Case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland. Rinsho Byori; 2009 Aug;57(8):746-51
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland.
  • Ductal adenocarcinoma of the lacrimal gland is extremely rare; to our knowledge, only seven de novo cases and one case of ductal adenocarcinoma ex pleomorphic adenoma have been reported in the literature.
  • Here, we report a case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland.
  • A 70-year-old Japanese female received the resection of the recurrent lacrimal gland tumor (second surgery), under the clinical diagnosis of recurrent pleomorphic adenoma, fifteen years after the initial surgical resection.
  • The resected tumor was composed of recurrent pleomorphic adenoma and adenocarcinoma.
  • Adenocarcinoma component showed infiltrative papillo-tubular or microcystic growth of carcinoma cells, which had pleomorphic large nuclei with prominent nucleoli and rich eosinophilic cytoplasm.
  • Accordingly, the diagnosis of ductal adenocarcinoma ex pleomorphic adenoma was made.
  • In the previously reported eight cases and the present case of lacrimal ductal adenocarcinomas, recurrence took place in 5 cases and two patients died from multiple metastases.
  • These data suggests that lacrimal ductal adenocarcinoma appears to have a poor prognosis, similar to salivary duct carcinoma, which is one of the most aggressive salivary carcinoma.
  • And further study is needed to clarify the clinicopathological features of the lacrimal ductal adenocarcinoma.
  • [MeSH-major] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Eye Neoplasms / diagnosis. Eye Neoplasms / pathology. Lacrimal Apparatus. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764409.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


21. Shi C, Scudiere JR, Cornish TC, Lam-Himlin D, Park JY, Fox MR, Montgomery EA: Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. Am J Surg Pathol; 2010 Sep;34(9):1344-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile.
  • Clear cell change is seen in <1% of colonic tubular adenomas (TAs) and remains incompletely characterized.
  • Associated adenocarcinomas can also demonstrate a clear cell phenotype.
  • Eleven TAs with at least focal clear cell change with or without associated invasive adenocarcinoma, from 10 patients were studied.
  • Two were associated with invasive clear cell adenocarcinoma.
  • The adenomas and adenocarcinomas ranged from 0.5 to 3.5 cm.
  • On immunohistochemical studies, the clear cells had decreased MUC2 labeling compared with the surrounding conventional adenoma in 9 of 11 (88%) cases, including the 2 clear cell adenocarcinomas.
  • Compared with background TA, both increased and decreased expression of CK7, CK20 (in quantity), and CDX2 (in intensity) were observed in the clear cells of TAs and adenocarcinomas.
  • One of the clear cell adenocarcinomas was CK20, CK7, CDX2 and the other was CK20, CK7, CDX2-focal positive.
  • Thus, although the clear cells have different MUC protein profiles than the background adenomatous epithelium, invasive clear cell adenocarcinomas retained the typical CK20(+)/CK7(-) profile of conventional adenocarcinomas.
  • Our results indicate that clear cell adenocarcinomas can be primary to the colorectum with identifiable precursors.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Colonic Neoplasms / pathology. Mucins / metabolism. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697252.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


22. Kim JH, Kim SS, Byun SW, Chang YJ, Kim JS, Kim JK, Cho HJ, Lim KW, Jung ES: [Double strand break of DNA in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2010 Jan;55(1):19-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Double strand break of DNA in gastric adenoma and adenocarcinoma].
  • The aim of this study was to define the differences in expression of 53BP1 and gamma-H2AX, the markers of DSB, among normal, gastric adenoma, and gastric adenocarcinoma tissues.
  • METHODS: Tissue microarray was made with the tissues taken from 121 patients who underwent gastrectomy for gastric adenocarcinoma, and 51 patients who underwent endoscopic mucosal resection for gastric adenoma.
  • The normal tissues were collected from histologically confirmed tissues with no cellular atypia obtained from the patients with gastric adenocarcinoma.
  • RESULTS: In gastric carcinoma cells, 53BP1 and gamma-H2AX were highly expressed as compared to normal epithelial cells and gastric adenoma (p<0.01).
  • There were no differences in the expression of 53BP1 and gamma-H2AX between normal epithelium and gastric adenoma.
  • The expression of 53BP1 in the adenoma with grade II and III atypism was more elevated than in those with grade I atypism.
  • The expression of 53BP1 and gamma-H2AX were not significantly different according to the clinicopathologic parameters in the patients with gastric adenocarcinoma.
  • CONCLUSIONS: The DSB in DNA seems to be associated with the development of gastric adenocarcinoma, but does not affect the premalignant adenoma cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. DNA Breaks, Double-Stranded. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098063.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones; 0 / Intracellular Signaling Peptides and Proteins; 0 / TP53BP1 protein, human; 0 / Tumor Suppressor p53-Binding Protein 1
  •  go-up   go-down


23. Lee DS, Kang SB, Baek JT, Nam SW, Lee KM, Ahn BM, Lee EH, Han SW, Chung IS: [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2005 Jun;45(6):394-400
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical expression of bcl-2, bcl-xL, bax, and p53 proteins according to the pathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in the gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal bcl-2, bcl-xL, bax, p53 antibodies were performed on paraffin embedded specimens from forty-one gastric adenomas and 100 gastric adenocarcinomas.
  • RESULTS: The expression rate of bcl-2 was higher in adenomas (34.2%), especially in high grade dysplasia (52.4%), than adenocarcinomas (2.0%).
  • The expression rate of bcl-xL was higher in adenocarcinomas (55.0%) than adenomas (22%).
  • The expression rate of the bax was higher in adenocarcinomas (58.0%) than adenomas (14.6%).
  • In the adenocarcinoma, the bax expression was significantly related with the depth of invasion, lymph node metastasis, and TNM stage.
  • The expression rate of p53 was higher in adenocarcinomas (64.0%) than adenomas (14.6%).
  • CONCLUSIONS: Bcl-2 protein would be related with the development of gastric adenoma, especially with high grade dysplasia.
  • Bcl-xL and p53 proteins would be involved in the development of relatively early stage of gastric adenocarcinoma but not in tumor progression.
  • Bax protein would be involved in the development of gastric adenocarcinoma and related with depth of invasion, lymph node metastasis, and TNM stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973073.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


24. Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS: Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine; 2006 Jan 21;33(2):66-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma.
  • We compared the expression patterns of leptin and of the long variant of the leptin receptor (Ob-Rb) between areas with non-ulcerated mucosa and with hyperplastic polyps, adenoma, or adenocarcinoma to evaluate the expression relative to different disease states.
  • Leptin and Ob-Rb were expressed in hyperplastic polyps, adenoma, and adenocarcinoma.
  • In the gastric adenocarcinoma, leptin was expressed significantly less in the poorly differentiated and diffuse-type groups than in the well-differentiated and moderately differentiated groups or in the intestinal type.
  • Based upon our findings, we suggest the possibility that leptin expression can have a pathophysiologic role about the differentiation or growth pattern of gastric adenocarcinoma.
  • A further series of experiments is necessary to elucidate the pathophysiological role of leptin in the differentiation of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Leptin / metabolism. Stomach / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434209.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


25. Lee SW, Kang SB, Kim YS, Nam SW, Lee DS, Lee HK, Han SW: [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2007 Mar;49(3):152-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical overexpression of c-erbB-2 and c-met proteins according to the histopathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal c-erbB-2 and c-met antibodies was performed on paraffin embedded specimens in 43 adenomas and 44 adenocarcinomas.
  • RESULTS: The expression rate of c-erbB-2 was higher in adenomas (91%) than adenocarcinomas (30%).
  • The expression rate of c-met was higher in adenocarcinomas (77%) than adenomas (49%).
  • In adenoma, the expression rate of c-met was higher in high grade dysplasia (94%) than in low grade dysplasia (22%).
  • In adenocarcinoma, c-met expression was significantly related with lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-met / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172343.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


26. Mäkinen MJ: Colorectal serrated adenocarcinoma. Histopathology; 2007 Jan;50(1):131-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal serrated adenocarcinoma.
  • Serrated adenocarcinoma is a recently described, distinct variant of CRC, accounting for about 7.5% of all CRCs and up to 17.5% of most proximal CRCs.
  • These lesions include hyperplastic-type aberrant crypt foci, hyperplastic polyps, sessile serrated adenomas, admixed polyps and serrated adenomas, and constitute the so-called 'serrated pathway', which is distinct from both the conventional adenoma-carcinoma pathway and the mutator pathway of hereditary non-polyposis CRC and is characterized by early involvement of oncogenic BRAF mutations, excess CpG island methylation (CIM) and subsequent low- or high-level DNA microsatellite instability (MSI).
  • Methylation of hMLH1 is likely to explain the increased frequency of high-level MSI (16%) and methylation of MGMT is postulated to explain the low-level MSI (29%) in serrated adenocarcinomas.
  • Reproducible histopathological criteria for serrated adenocarcinoma have recently been established and they have been qualified by DNA expression analysis for 7928 genes, showing clustering of serrated adenocarcinomas into a molecular entity apart from conventional adenocarcinoma, and representing with distinct down-regulation of EPHB2, PTCH and up-regulation of HIF1alpha.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204027.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 209
  •  go-up   go-down


27. Haghpanah V, Shooshtarizadeh P, Heshmat R, Larijani B, Tavangar SM: Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Appl Immunohistochem Mol Morphol; 2006 Dec;14(4):422-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma.
  • This retrospective study of thyroid histologic samples aimed to assess the clinical usefulness of survivin immunostaining for discrimination between follicular adenoma and carcinoma of thyroid.
  • Immunohistochemical staining for survivin was performed on 41 lesions from patients who had undergone surgery for either follicular adenoma or carcinoma of thyroid.
  • Survivin expression was significantly (P < 0.005) higher in the cases that received a diagnosis of carcinoma in comparison with follicular adenomas cases.
  • Our results showed potential value of survivin in discrimination between follicular thyroid adenoma and follicular thyroid carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122639.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


28. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • Adenocarcinomas of the bladder are rare, with the diagnosis dependent on exclusion of secondary involvement by direct extension or metastatic spread from other sites.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • We identified 37 primary infiltrating adenocarcinomas of the bladder, which included signet ring cell carcinomas (n=11), urachal adenocarcinomas (n=5), and enteric adenocarcinoma (n=21).
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • Of the 37 adenocarcinomas, all were negative for PSA and PSAP (0/37; 0%).
  • In contrast, a minority of bladder adenocarcinomas was labeled with the prostate antigens P501S and PSMA.
  • P501S showed moderate diffuse cytoplasmic staining in 4/37 cases (11%), including 3 enteric-type adenocarcinomas and 1 mucinous adenocarcinoma.
  • Additionally, 1 case of adenocarcinoma in situ demonstrated diffuse cytoplasmic staining for P501S.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • PSMA showed diffuse cytoplasmic staining in 4/37 (11%) infiltrating adenocarcinomas (including 1 signet ring carcinoma and 3 enteric-type adenocarcinomas), and in 1 case of adenocarcinoma in situ.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


29. Tatsumi N, Mukaisho K, Mitsufuji S, Tatsumi Y, Sugihara H, Okanoue T, Hattori T: Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases. Dig Dis Sci; 2005 Sep;50(9):1741-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases.
  • The entity of serrated adenoma of the colorectum was first proposed in 1990, and it was characterized as epithelial neoplasia combining the architectural features of a hyperplastic polyp with the cytological features of an adenoma.
  • Over the past few years, various clinicopathological studies on serrated adenoma have been reported, but its histogenesis remains unclear.
  • Recently the existence of a "serrated neoplasia pathway" leading to malignancy, which is different from the so-called adenoma-carcinoma sequence, has been discussed.
  • Yao et al. reported that hyperplastic polyps and serrated adenomas share a common cell lineage with gastric differentiation.
  • To clarify the existence of the serrated neoplasia pathway, we performed immunohistochemical staining of cytokeratin 7 (CK7) and cytokeratin 20 (CK20), which are commonly used to determine the primary site of a metastatic lesion, and we examined the pattern of CK7/CK20 expression in various colorectal lesions including 44 serrated adenomas, 25 hyperplastic polyps, 20 traditional adenomas, and 48 carcinomas.
  • An obvious difference existed in the pattern of CK7/CK20 expression between the serrated lesions (hyperplastic polyps and serrated adenomas) and others.
  • The majority of serrated adenomas and hyperplastic polyps presented a CK7+/CK20+ pattern, whereas most conventional adenomas and adenocarcinomas expressed CK7-/CK20+.
  • Adenocarcinoma developing in serrated adenoma also presented a CK7+/CK20+ pattern.
  • Taken together with the present results, a distinct pathway of colorectal carcinogenesis must exist, which is different from the adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / blood. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Intermediate Filament Proteins / biosynthesis. Keratins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] J Pathol. 2000 Mar;190(4):444-9 [10699993.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Acta Histochem. 1991;91(1):21-3 [1724863.001]
  • [Cites] J Gastroenterol. 2002;37(6):467-70 [12108682.001]
  • [Cites] Gut. 2002 Aug;51(2):200-6 [12117880.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Virchows Arch. 2001 Oct;439(4):512-22 [11710638.001]
  • [Cites] Ann N Y Acad Sci. 1985;455:282-306 [2417517.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1884-7 [12085180.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):567-80 [1696264.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):641-55 [1690512.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Histol Histopathol. 2002 Apr;17 (2):445-54 [11962749.001]
  • [Cites] Pathol Int. 2001 Mar;51(3):215-20 [11328539.001]
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] J Pathol. 1999 Apr;187(5):511-7 [10398114.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):758-63 [11937308.001]
  • [Cites] Pathology. 2002 Dec;34(6):548-55 [12555993.001]
  • [Cites] J Pathol. 1991 Oct;165(2):145-52 [1720817.001]
  • (PMID = 16133982.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


30. Takahashi S, Takada K, Kawano Y, Miyanishi K, Ishiwatari H, Hayashi T, Sagawa T, Sato T, Sato Y, Takimoto R, Kobune M, Kuroiwa G, Hirayama M, Tobioka H, Hirata K, Omatsu M, Hasegawa T, Kato J: [Cholangiocarcinoma with bile duct adenoma and hamartoma-like lesion in the bile duct]. Nihon Shokakibyo Gakkai Zasshi; 2010 Mar;107(3):461-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cholangiocarcinoma with bile duct adenoma and hamartoma-like lesion in the bile duct].
  • The tumor was subsequently resected, and histopathology showed a moderately differentiated adenocarcinoma.
  • In addition, cystically dilated ductules resembling bile duct hamartoma and bile duct adenoma adjacent to the tumor were found, but with no area of transition among them.
  • [MeSH-major] Adenoma / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Hamartoma / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20203450.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Hoch BL, Wu M, Lewis M, Gan L, Burstein DE: An immunohistochemical study of XIAP expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma. J Oral Pathol Med; 2008 Nov;37(10):634-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of XIAP expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma.
  • The biological progression from pleomorphic adenoma (PA) to carcinoma ex pleomorphic adenoma (CXPA) has been poorly understood.
  • CONCLUSION: Increased expression of XIAP from PA to cellular PA to CXPA and in atypical cells within cellular areas of PA adds to our growing understanding of defective apoptotic pathways in malignant transformation in this group of salivary gland tumors and suggests an adenoma to adenocarcinoma model of progression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Cell Transformation, Neoplastic / metabolism. Salivary Gland Neoplasms / metabolism. X-Linked Inhibitor of Apoptosis Protein / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673415.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


32. Lee CH, Bang SH, Lee SK, Song KY, Lee IC: Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ. World J Gastroenterol; 2005 Apr 7;11(13):1937-45
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ.
  • METHODS: We analyzed the expression profiles of normal gastric pit, tubular adenoma and carcinoma in situ using microdissected cells from routine gastric biopsies.
  • RESULTS: In comparison with normal pit, adenoma/carcinoma showed 504 up-regulated and 29 down-regulated genes at the expected false significance rate 0.15%.
  • The differential expression between adenoma and carcinoma in situ was subtle: 50 and 22 genes were up-, and down-regulated in carcinomas at the expected false significance rate of 0.61%, respectively.
  • Differentially expressed genes were grouped according to patterns of the sequential changes for the 'tendency analysis' in the gastric mucosa-adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma in Situ / genetics. Gene Expression Profiling. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800983.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305714
  •  go-up   go-down


33. Curran AE, Allen CM, Beck FM, Damm DD, Murrah VA: Distinctive pattern of glial fibrillary acidic protein immunoreactivity useful in distinguishing fragmented pleomorphic adenoma, canalicular adenoma and polymorphous low grade adenocarcinoma of minor salivary glands. Head Neck Pathol; 2007 Sep;1(1):27-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive pattern of glial fibrillary acidic protein immunoreactivity useful in distinguishing fragmented pleomorphic adenoma, canalicular adenoma and polymorphous low grade adenocarcinoma of minor salivary glands.
  • STUDY DESIGN: Glial fibrillary acidic protein (GFAP) reactivity was examined among 78 minor salivary gland neoplasms: 27 canalicular adenomas (CAA), 21 pleomorphic adenomas (PA) and 30 polymorphous low grade adenocarcinomas (PLGA).
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Pleomorphic / diagnosis. Glial Fibrillary Acidic Protein / metabolism. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):401-5 [10705394.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Feb;91(2):194-9 [11174597.001]
  • [Cites] Am J Clin Pathol. 1977 Mar;67(3):272-8 [842502.001]
  • [Cites] Am J Pathol. 1990 Nov;137(5):1143-55 [1700618.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(4):339-48 [1708927.001]
  • [Cites] J Laryngol Otol. 1991 Dec;105(12):1057-60 [1664847.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jun;83(6):691-5 [9195625.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):997-1006 [9833827.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Mar;87(3):346-50 [10102598.001]
  • [Cites] Electrophoresis. 1999 Apr-May;20(4-5):1087-91 [10344289.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):207-19 [10421256.001]
  • (PMID = 20614277.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  • [Other-IDs] NLM/ PMC2807497
  • [Keywords] NOTNLM ; Canalicular adenoma / Glial fibrillary acidic protein / Immunohistochemistry / Pleomorphic adenoma / Polymorphous low-grade adenocarcinoma / Salivary gland neoplasms
  •  go-up   go-down


34. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H: Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer; 2009 Aug 15;125(4):894-901
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
  • The identification of high-risk patients with thyroid cancer and the preoperative differentiation between follicular adenoma and carcinoma remain clinically challenging.
  • Tumor/normal tissue was collected from 69 prospectively followed patients with thyroid carcinomas (papillary, medullary, follicular and anaplastic, PTC, MTC, FTC and ATC) or follicular adenomas.
  • Carcinomas except MTC expressed significantly more u-PAR/MMPs than adenomas/normal tissues, this being associated with advanced pT- or M-stages.
  • MMP-1 and MMP-9 were significantly higher in follicular carcinomas than in adenomas.
  • This is the first study to suggest MMP-1/-9 as significant differentiation markers between follicular adenoma and follicular carcinoma.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Receptors, Urokinase Plasminogen Activator / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Blotting, Western. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Electrophoretic Mobility Shift Assay. Female. Humans. Immunoenzyme Techniques. Luciferases. Male. Matrix Metalloproteinase 7 / metabolism. Middle Aged. Prognosis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480010.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Urokinase Plasminogen Activator; EC 1.13.12.- / Luciferases; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


35. Futagami S, Hiratsuka T, Shindo T, Horie A, Hamamoto T, Suzuki K, Kusunoki M, Miyake K, Gudis K, Crowe SE, Tsukui T, Sakamoto C: Expression of apurinic/apyrimidinic endonuclease-1 (APE-1) in H. pylori-associated gastritis, gastric adenoma, and gastric cancer. Helicobacter; 2008 Jun;13(3):209-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of apurinic/apyrimidinic endonuclease-1 (APE-1) in H. pylori-associated gastritis, gastric adenoma, and gastric cancer.
  • To investigate the role of APE-1 in the development of gastric cancer, we examined APE-1 expression and localization in cultured cells and gastric biopsies from patients with H. pylori-infected gastritis or gastric adenoma, and from surgically resected gastric cancer.
  • METHODS: APE-1 mRNA and protein expression were determined in H. pylori (CagA+) water-extract protein (HPWEP)-stimulated MKN-28 cells, gastric adenocarcinoma cell-line (AGS) cells, and human peripheral macrophages by real-time polymerase chain reaction and Western blot analysis.
  • Localization of APE-1 and IkappaBalpha phosphorylation in gastric adenoma and gastric cancer tissues were evaluated by single- and double-label immunohistochemistry.
  • APE-1 expression was mainly localized in epithelial cells within gastric adenoma and in mesenchymal cells of gastric cancer tissues.
  • APE-1 expression in gastric cancer tissues was significantly reduced compared to that in H. pylori-infected gastric adenoma, while 8-OHdG index and IkappaBalpha phosphorylation levels did not differ between these two neoplastic tissue types.
  • Co-localization of APE-1 and IkappaBalpha phosphorylation was observed not in gastric cancer cells but in gastric adenoma cells.
  • CONCLUSION: H. pylori infection is associated with increased APE-1 expression in human cell lines and in gastric tissues from subjects with gastritis and gastric adenomas.
  • The observed distinct expression patterns of APE-1 and 8-OHdG in gastric adenoma and gastric cancer tissues may provide insight into the progression of these conditions and warrants further investigation.
  • [MeSH-minor] Adenoma / enzymology. Adenoma / genetics. Adenoma / microbiology. Adult. Aged. Cells, Cultured. Female. Gastric Mucosa / metabolism. Gastric Mucosa / microbiology. Humans. Male. Middle Aged. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466396.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK061769
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase
  •  go-up   go-down


36. Shen J, Liu J, Xie Y, Diwan BA, Waalkes MP: Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic exposure. Toxicol Sci; 2007 Feb;95(2):313-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic exposure.
  • Lung adenoma and adenocarcinoma from adult female mice exposed to arsenic in utero showed widespread, intense nuclear ER-alpha expression.
  • In contrast, normal adult lung and diethylnitrosamine-induced lung adenocarcinoma showed little evidence of ER-alpha expression.
  • ER-alpha activation was specifically associated with arsenic-induced lung adenocarcinoma and adenoma but not with nitrosamine-induced lung tumors.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2000 Feb;190(2):133-42 [10657010.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1243-55 [14617798.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Curr Oncol Rep. 2004 Jul;6(4):259-67 [15161576.001]
  • [Cites] Clin Lung Cancer. 2004 May;5(6):353-9 [15217534.001]
  • [Cites] Growth Horm IGF Res. 2004 Aug;14(4):261-9 [15231294.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):366-76 [15276416.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):394-404 [15276419.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1775-85 [9846968.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 7;326(1):218-27 [15567174.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Jan;32(1):65-71 [15514114.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):316-9 [15627066.001]
  • [Cites] J Soc Gynecol Investig. 2005 Jan;12(1):58-64 [15629674.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1459-70 [15735034.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):101-7 [15788642.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3796-805 [15867376.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3212-8 [15886308.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9 [15937110.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 15;206(3):288-98 [16039940.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11287-91 [16357134.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):404-11 [16507464.001]
  • [Cites] Toxicol Sci. 2006 Jun;91(2):372-81 [16543296.001]
  • [Cites] Toxicology. 2006 Jul 5;224(1-2):147-55 [16753250.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305 [16712894.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Annu Rev Med. 2003;54:73-87 [12471176.001]
  • [Cites] Expert Rev Anticancer Ther. 2002 Dec;2(6):709-35 [12503217.001]
  • [Cites] Biochem Cell Biol. 2002;80(3):335-41 [12123286.001]
  • [Cites] Prostate. 2002 Aug 1;52(3):236-44 [12111698.001]
  • [Cites] Lung Cancer. 2002 May;36(2):125-32 [11955646.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):46-53 [11940206.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 25;188(1-2):125-40 [11911952.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61 [11312654.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Jul 1;166(1):24-35 [10873715.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • (PMID = 17077188.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / NIH0011069698; United States / Intramural NIH HHS / / ; United States / PHS HHS / / NIH0011069698; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / Carcinogens, Environmental; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite
  • [Other-IDs] NLM/ NIHMS33564; NLM/ PMC2692318
  •  go-up   go-down


37. Ciurea S, Matei E, Petrisor P, Luca L, Boros M, Herlea V, Popescu I: Gallbladder adenoma with focal adenocarcinoma. Chirurgia (Bucur); 2008 May-Jun;103(3):355-8
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder adenoma with focal adenocarcinoma.
  • True neoplastic GB polyps are represented mainly by adenomas.
  • The case of a 52-year old male patient with an adenomatous polyp of the GB with focal adenocarcinoma is presented.
  • [MeSH-major] Adenocarcinoma. Adenoma. Gallbladder Neoplasms. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717288.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


38. Bagwan IN, Cook G, Mudan S, Wotherspoon A: Unusual presentation of metastatic adenocarcinoma. World J Surg Oncol; 2007;5:116
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of metastatic adenocarcinoma.
  • BACKGROUND: The most common tumours of the adrenal gland are adenoma, pheochromocytoma, adrenocortical carcinoma, and metastases.
  • CASE PRESENTATION: A 52 year-old female was diagnosed with oesophageal adenocarcinoma and treated with oesophagectomy and adjuvant chemotherapy.
  • Adrenalectomy was performed and histological examination revealed metastatic adenocarcinoma within an adrenal adenoma.
  • CONCLUSION: The present case highlights the unusual behaviour of an oesophageal adenocarcinoma causing metastasis to an adrenocortical adenoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 2005 Dec;52(6):785-8 [16410674.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1624-33 [16518827.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1795-9 [11752075.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] AJR Am J Roentgenol. 1996 Oct;167(4):891-2 [8819376.001]
  • [Cites] Surgery. 2004 Dec;136(6):1289-96 [15657589.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4924-9 [15914530.001]
  • (PMID = 17949483.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2100056
  •  go-up   go-down


39. Hong R, Lim SC: Pathological significance of connexin 26 expression in colorectal adenocarcinoma. Oncol Rep; 2008 Apr;19(4):913-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological significance of connexin 26 expression in colorectal adenocarcinoma.
  • This study was conducted to determine the level of expression and cellular localization of connexin 26 (Cx26) and the expression of p53 in colorectal adenocarcinoma as well as their relationship to clinicopathological features.
  • Immunohistochemical staining was performed in 130 colorectal adenocarcinoma cases.
  • There was a statistical significant difference in the Cx26 expression level among normal epithelium (NE), adenomas and adenocarcinomas (p<0.001).
  • Of the 130 adenocarcinomas, 48.5% were positive for Cx26.
  • All of the adenoma and NE samples were positive for Cx26 expression; however, the level of expression of Cx26 in adenomas was smaller than the level of expression for NE.
  • Cytoplasmic staining for Cx26 was observed in the adenocarcinomas (23.8%), but was not observed in the adenoma and NE samples.
  • Expression of p53 was positive for 50% of the adenocarcinomas, and the level of p53 was increased in a reverse proportion to the level of Cx26 intercellular staining.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Connexins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


40. Nelson KK, Gattuso P, Xu X, Prinz RA: Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy. Surgery; 2010 Oct;148(4):654-60; discussion 660
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy.
  • This study determines whether 3 molecules, Patched, Smoothened, and Sonic Hedgehog, involved in the Sonic Hedgehog pathway are overexpressed equally in synchronous follicular thyroid adenoma and papillary thyroid carcinoma.
  • METHODS: Eighteen patients with synchronous follicular thyroid adenoma and papillary thyroid carcinoma underwent thyroidectomy.
  • Patched expression was detected in 5 of 13 (38%) follicular adenomas and 5 of 12 (42%) papillary carcinomas.
  • Smoothened was expressed in 4 of 13 (31%) follicular adenomas and 3 of 13 (23%) papillary carcinomas.
  • Sonic Hedgehog was expressed in 4 of 13 (31%) follicular adenomas and 11 of 13 (85%) papillary carcinomas.
  • CONCLUSION: Expression of the 3 molecules involved in the Sonic Hedgehog pathway was similar in follicular thyroid adenoma, but Sonic Hedgehog expression was a more sensitive indicator of malignancy in papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Adenoma / metabolism. Hedgehog Proteins / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Multiple Primary. Predictive Value of Tests. Thyroid Gland / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20797751.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / SHH protein, human
  •  go-up   go-down


41. Paleri V, Robinson M, Bradley P: Polymorphous low-grade adenocarcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg; 2008 Apr;16(2):163-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma of the head and neck.
  • PURPOSE OF REVIEW: Polymorphous low-grade adenocarcinoma is an entity described in 1984.
  • The natural history of polymorphous low-grade adenocarcinoma is distinct from other malignant salivary tumours.
  • RECENT FINDINGS: Polymorphous low-grade adenocarcinoma is a slow-growing tumour that is locally invasive.
  • The morphological features can resemble pleomorphic adenoma and adenoid cystic carcinoma.
  • The role of radiation therapy is not clear in the management of polymorphous low-grade adenocarcinoma.
  • SUMMARY: Polymorphous low-grade adenocarcinoma is primarily a pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327037.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


42. Ayadi L, Chaâbouni S, Dhouib H, Abbès K, Dhouib M, Makni S, Abdelmoula M, Ghorbel A, Khabir A, Boudawara T: [Polymorphous low-grade adenocarcinoma: about two cases]. Tunis Med; 2009 Jun;87(6):403-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polymorphous low-grade adenocarcinoma: about two cases].
  • BACKGROUND: Polymorphous low-grade adenocarcinoma (APBG) is a variant of malignant tumour of minor salivary glands usually arising in the palate.
  • A biopsy concluded to a pleomorphic adenoma.
  • CONCLUSION: APBG is characterised by a morphologic diversity and a cytologic uniformity that may cause a diagnostic dilemma especially with adenoid cystic carcinoma and pleomorphic adenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927787.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


43. Xiao GQ, Burstein DE, Miller LK, Unger PD: Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Jun;130(6):805-10
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
  • CONTEXT: Nephrogenic adenoma is a rare benign lesion of the urinary tract.
  • Owing to its strong association with a history of urinary tract irritation, nephrogenic adenoma was initially thought to originate from urothelial metaplasia; however, no solid proof of this association has been found.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic carcinoma, particularly when dealing with lesions from the prostatic urethra.
  • OBJECTIVE: To elucidate a possible histogenic relationship between nephrogenic adenoma and renal tubules, and also to evaluate the role of immunohistochemistry in the diagnostic distinction between nephrogenic adenoma and prostate carcinoma.
  • DESIGN: Immunohistochemical studies were performed for P504S, prostate-specific antigen, CD10, p63, and epithelial membrane antigen on 9 cases of nephrogenic adenoma, 10 cases of normal renal parenchyma, and 10 cases of prostatic tissue, both benign and malignant.
  • RESULTS: Nephrogenic adenoma shares the same immunohistochemical profile as distal renal tubules: both are positive for P504S and epithelial membrane antigen and negative for p63, CD10, and prostate-specific antigen.
  • Prostatic adenocarcinoma tissue was positive for P504S and prostate-specific antigen, and normal prostatic gland tissue was positive for prostate-specific antigen and negative for P504S; p63-stained basal cells in normal prostatic gland tissue but did not react with prostatic adenocarcinoma tissue.
  • CONCLUSION: These findings provide supporting evidence that nephrogenic adenoma is derived from distal renal tubules.
  • Our results also demonstrated that the combination of P504S and prostate-specific antigen with epithelial membrane antigen is a valuable tool in distinguishing prostatic carcinoma from nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Immunohistochemistry / methods. Prostatic Neoplasms / diagnosis. Urologic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740031.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


44. Marino M, Galluzzo P, Leone S, Acconcia F, Ascenzi P: Nitric oxide impairs the 17beta-estradiol-induced apoptosis in human colon adenocarcinoma cells. Endocr Relat Cancer; 2006 Jun;13(2):559-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide impairs the 17beta-estradiol-induced apoptosis in human colon adenocarcinoma cells.
  • By contrast, E2 reduces the incidence of colon adenoma and carcinoma by about 30%.
  • We report the genomic and non-genomic E2-estrogen receptor (ER) beta-induced effects in human colon adenocarcinoma.
  • However, NO impaired the E2-induced pro-apoptotic cascade in human colon adenocarcinoma cells by inhibiting caspase-3.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / drug effects. Caspase Inhibitors. Colonic Neoplasms / metabolism. Estrogen Receptor beta / antagonists & inhibitors. Nitric Oxide / toxicity

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728582.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caspase Inhibitors; 0 / Estrogen Receptor beta; 31C4KY9ESH / Nitric Oxide; 4TI98Z838E / Estradiol; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; K848JZ4886 / Cysteine
  •  go-up   go-down


45. Park JK, Hong R, Kim KJ, Lee TB, Lim SC: Significance of p-STAT3 expression in human colorectal adenocarcinoma. Oncol Rep; 2008 Sep;20(3):597-604
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p-STAT3 expression in human colorectal adenocarcinoma.
  • To examine the relationship between p-STAT3 and the clinicopathological parameters of colorectal adenocarcinoma (CRA), we initially conducted immunohistochemical (IHC) analyses on formalin-fixed tissues.
  • A total of 127 invasive CRA, 20 colorectal adenomas and 20 normal mucosae were obtained.
  • The statistically significant difference of immunoreactivity for p-STAT3 between the CRA and adenoma, and between the CRA and normal mucosae was identified.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma in Situ / genetics. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Colon / metabolism. Colon / pathology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Neoplasm Staging. Phosphorylation. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695911.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human
  •  go-up   go-down


46. Hansel DE, Nadasdy T, Epstein JI: Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1231-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma.
  • Nephrogenic adenomas demonstrate a variety of morphologic patterns that may occasionally be confused with malignant processes, including urothelial and prostatic carcinoma.
  • In this series, we describe 8 cases of nephrogenic adenoma that contain an admixture of the classic tubular form of nephrogenic adenoma and an unusual spindled and fibromyxoid form of nephrogenic adenoma that closely mimics infiltrating carcinoma.
  • In all cases, the classic tubular form of nephrogenic adenoma composed only a small proportion of the lesion, whereas the remainder consisted of compressed spindled cells within a fibromyxoid background, with only rare tubular and cordlike structures.
  • All 8 patients were elderly men who had a prior or concurrent history of acinar prostate cancer (n=4), combined acinar prostate and urothelial carcinoma (n=1), urothelial-type adenocarcinoma of the prostate (n=1), bladder urothelial carcinoma (n=1), or no prior reported prostatic or urothelial abnormalities (n=1).
  • This case series is the first report of a fibromyxoid subtype of nephrogenic adenoma.
  • Awareness of this entity and the use of ancillary techniques can aid in the diagnosis of this unusual form of nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Fibroma / pathology. Urologic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667548.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


47. Keramidas EG, Miller G, Revelos K, Kitsanta P, Page RE: Aggressive digital papillary adenoma-adenocarcinoma. Scand J Plast Reconstr Surg Hand Surg; 2006;40(3):189-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenoma-adenocarcinoma.
  • Aggressive digital papillary adenocarcinoma and aggressive digital papillary adenoma are rare tumours of the sweat glands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687341.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Abiko K, Baba T, Ogawa M, Mikami Y, Koyama T, Mandai M, Konishi I: Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus. Pathol Int; 2010 Jan;60(1):42-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus.
  • Primary mucinous adenocarcinomas of the uterine corpus are typically low grade and frequently associated with endometrial hyperplasia and/or ordinary endometrioid adenocarcinoma, but may appear as a heterogeneous group of neoplasms.
  • Microscopic examination of hysterectomy specimens indicated highly differentiated mucinous adenocarcinoma diffusely infiltrating the portion of adenomyosis of the corpus.
  • HIK1083 and MUC6 immunohistochemistry indicated a gastric phenotype of the tumor, as seen in cases of prototypical minimal deviation adenocarcinoma (MDA) of the cervix.
  • In summary, mucinous endometrial adenocarcinoma rarely shows features similar to MDA of the cervix.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055951.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


49. Fujimori S, Kishida T, Kobayashi T, Sekita Y, Seo T, Nagata K, Tatsuguchi A, Gudis K, Yokoi K, Tanaka N, Yamashita K, Tajiri T, Ohaki Y, Sakamoto C: Helicobacter pylori infection increases the risk of colorectal adenoma and adenocarcinoma, especially in women. J Gastroenterol; 2005 Sep;40(9):887-93
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori infection increases the risk of colorectal adenoma and adenocarcinoma, especially in women.
  • The purpose of this study was to assess the association between H. pylori infection and the risk of colorectal adenoma and adenocarcinoma, and to evaluate any differences on the basis of sex.
  • The odds ratios (ORs) for H. pylori-positive patients with colorectal adenoma and adenocarcinoma, and for tumor patients with either adenoma or adenocarcinoma were calculated.
  • RESULTS: Among the H. pylori-negative patients, there were 52 patients without tumor, 63 with adenoma, 27 with adenocarcinoma, and 90 with tumor.
  • Pooling all subjects, those infected with H. pylori had a significantly increased OR for adenoma, adenocarcinoma, or tumor, compared to H. pylori-free patients (OR, 1.60, 1.80, and 1.66, respectively).
  • For female H. pylori-positive subjects, the risk of having adenocarcinoma or tumor was significantly higher than that for their H. pylori-free counterparts, while for male H. pylori-positive and -negative subjects, there was no such significant difference.
  • CONCLUSIONS: The results therefore suggest that, in patients aged 40-80 years, H. pylori infection increased the risk of colorectal adenoma and adenocarcinoma, with significantly higher risks for female patients.
  • [MeSH-major] Adenocarcinoma / etiology. Adenoma / etiology. Colorectal Neoplasms / etiology. Helicobacter Infections / complications

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2005 Sep;40(9):919-20 [16211355.001]
  • [Cites] Carcinogenesis. 1997 Dec;18(12):2353-9 [9450481.001]
  • [Cites] Gut. 1993 Jun;34(6):752-6 [8314506.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Dig Dis Sci. 1989 Feb;34(2):171-4 [2914535.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):84-8 [11197293.001]
  • [Cites] Helicobacter. 2003 Feb;8(1):29-35 [12603614.001]
  • [Cites] Mol Microbiol. 1999 May;32(3):459-70 [10320570.001]
  • [Cites] J Clin Gastroenterol. 1997 Dec;25(4):605-7 [9451672.001]
  • [Cites] Isr Med Assoc J. 2000 Jan;2(1):6-9 [10892362.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2691-4 [8194007.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):762-3 [7563155.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1197-207 [9506368.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1535-9 [9276627.001]
  • [Cites] Gynecol Endocrinol. 1993 Dec;7(4):251-8 [8147234.001]
  • [Cites] Biomed Pharmacother. 1994;48(3-4):157-66 [7993980.001]
  • [Cites] Gut. 1997 Sep;41(3):330-2 [9378387.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]
  • [Cites] Am J Physiol. 1986 Nov;251(5 Pt 1):G597-601 [3777167.001]
  • [Cites] Am J Gastroenterol. 1993 Dec;88(12):2038-43 [8249971.001]
  • [Cites] Cancer Res. 1988 Jun 1;48(11):3035-9 [3365693.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Mar;15(3):277-83 [10764028.001]
  • [Cites] Digestion. 1999;60(3):210-5 [10343134.001]
  • [Cites] JAMA. 1999 Dec 15;282(23):2240-5 [10605976.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] Lancet. 1992 Nov 14;340(8829):1194-5 [1359263.001]
  • [Cites] Lancet. 1994 Jun 25;343(8913):1636-7 [7911939.001]
  • [Cites] Gut. 1993 Jul;34(7):888-92 [8344574.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):567-73 [12189558.001]
  • [Cites] Gut. 2000 Dec;47(6):820-4 [11076881.001]
  • [Cites] Gut. 1993 Aug;34(8):1032-7 [8174948.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1103-7 [12439934.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1121-2 [10201512.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2508-17 [15184428.001]
  • [Cites] Biochim Biophys Acta. 2003 Dec 5;1624(1-3):88-97 [14642818.001]
  • [Cites] Lancet. 1993 May 22;341(8856):1348 [8098476.001]
  • (PMID = 16211345.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Caria P, Vanni R: Cytogenetic and molecular events in adenoma and well-differentiated thyroid follicular-cell neoplasia. Cancer Genet Cytogenet; 2010 Nov;203(1):21-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and molecular events in adenoma and well-differentiated thyroid follicular-cell neoplasia.
  • Thyroid adenoma is the benign counterpart of follicular carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Chromosome Aberrations. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20951315.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX8-PPARgamma fusion protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human
  •  go-up   go-down


51. Yoshimi R, Takeno M, Yamanaka S, Shiina M, Kirino Y, Takeda Y, Sekiguchi A, Kobayashi H, Ihata A, Motoji K, Ohno S, Ueda A, Soga T, Ishigatsubo Y: Systemic sclerosis and pseudomesotheliomatous adenocarcinoma of the lung. Mod Rheumatol; 2006;16(3):165-8
MedlinePlus Health Information. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic sclerosis and pseudomesotheliomatous adenocarcinoma of the lung.
  • In the postmortem examination, the tumor was pathologically diagnosed as pseudomesotheliomatous adenocarcinoma (PMA) of the lung, classified into pleomorphic carcinoma with adenocarcinoma component according to the new World Health Organization guidelines.

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767555.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • PAX2 encodes a transcription factor necessary in the development of the Wolffian duct system, and the protein is expressed in several tumors of mesonephric origin, including renal cell carcinoma, Wilm tumor, and nephrogenic adenoma.
  • We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • We demonstrated that PAX2 was strongly and diffusely expressed in mesonephric remnants (6 of 6) and in mesonephric hyperplasia (18 of 18); however, no expression was noted in mesonephric adenocarcinoma (0 of 1).
  • In contrast, only 2 cases of endocervical adenocarcinoma were positive for PAX2 [invasive adenocarcinoma of the minimal deviation type (0 of 5), usual type (1 of 22), and endometrioid type (1 of 1)].
  • Adjacent adenocarcinoma in situ, as well as cases of pure adenocarcinoma in situ (0 of 6), were also PAX2 negative.
  • PAX2 expression in the 2 positive endocervical adenocarcinomas was patchy and weak.
  • Most (11 of 15) stage II endometrial endometrioid adenocarcinomas lacked PAX2 expression but 1 of 10 grade 1 tumors and 3 of 5 grade 2 tumors did express PAX2.
  • These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061933.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human
  •  go-up   go-down


53. Cardona DM, Zhang X, Liu C: Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. Am J Clin Pathol; 2009 Dec;132(6):877-82
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma.
  • Expression of CPS1 in invasive SI adenocarcinoma seems to be lost.
  • We retrospectively collected 36 total specimens, which included 31 SI adenomas and 21 adenocarcinomas.
  • The normal SI mucosa, all 34 cases of duodenitis, and all 29 adenomas with low-grade dysplasia demonstrated diffuse Hep Par 1 expression.
  • Of the 21 invasive adenocarcinomas, 15 lost antigen expression (71%).
  • Western blot analysis confirmed the immunohistochemical findings, with strong CPS1 expression within the normal mucosa and adenoma and complete loss in the invasive tumor.
  • [MeSH-major] Adenocarcinoma / enzymology. Carbamoyl-Phosphate Synthase (Ammonia) / metabolism. Duodenal Neoplasms / enzymology. Duodenum / enzymology
  • [MeSH-minor] Adenoma / enzymology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Duodenitis / enzymology. Duodenitis / pathology. Humans. Immunohistochemistry. Intestinal Mucosa / enzymology. Intestinal Mucosa / pathology. Neoplasm Invasiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926579.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.4.16 / Carbamoyl-Phosphate Synthase (Ammonia)
  •  go-up   go-down


54. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS: Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology; 2010 Jan;56(2):229-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma.
  • METHODS AND RESULTS: Immunohistochemistry staining for PTEN was performed on a tissue microarray of 19 samples of normal colonic mucosa, 14 adenomatous polyps, 482 adenocarcinomas and 56 metastatic lymph nodes.
  • However, only 241 (50.0%) of the 482 colorectal adenocarcinomas and 26 (46.4%) of the 56 metastatic lymph nodes were positive for PTEN.
  • On univariate survival analysis, patients with PTEN- adenocarcinoma revealed a poor overall and disease-free survival (P = 0.030 and P = 0.046, respectively).
  • CONCLUSIONS: Nuclear PTEN expression gradually decrease during the normal-adenoma-adenocarcinoma-metastasis sequence, which suggests an important role for PTEN in carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenomatous Polyps / metabolism. Cell Nucleus / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. PTEN Phosphohydrolase / metabolism. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102402.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


55. Cui Y, Tian M, Zong M, Teng M, Chen Y, Lu J, Jiang J, Liu X, Han J: Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma. Pancreatology; 2009;9(1-2):89-98
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma.
  • METHODS: To better understand the limitations of potential protein biomarkers in pancreatic cancer, we employed two-dimensional difference gel electrophoresis technology and tandem mass spectrometry to study protein expression profiles in pancreatic cancer tissues, benign pancreatic adenoma and normal adjacent pancreas.
  • Our study demonstrated that three candidate pancreatic ductal adenocarcinoma biomarkers identified in previous studies, fructose-bisphosphate aldolase A, alpha-smooth muscle actin and vimentin, were also overexpressed in pancreatic cystadenoma, which might lower their further utility as biomarkers for pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077459.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chaperonin 60; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human; 0 / Vimentin; 117896-08-9 / nucleophosmin; EC 1.1.1.- / aflatoxin B1 aldehyde reductase; EC 1.1.1.21 / Aldehyde Reductase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  •  go-up   go-down


56. Strul H, Kariv R, Leshno M, Halak A, Jakubowicz M, Santo M, Umansky M, Shirin H, Degani Y, Revivo M, Halpern Z, Arber N: The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40-80 years. Am J Gastroenterol; 2006 Feb;101(2):255-62
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40-80 years.
  • OBJECTIVES: To evaluate the prevalence and anatomic location of CR adenoma and carcinoma and the morbidity of colonoscopy in individuals at average risk for CR cancer (CRC).
  • In the 50-75 age group, the prevalence of overall adenoma, advanced neoplasia, and cancer was 21.3%, 6.7%, and 1.2%, respectively.
  • Among the elderly, the prevalence of overall adenoma, advanced neoplasia, and cancer reached 26.0%, 14.3%, and 2.6%, respectively.
  • In the young group, 9.8% had overall neoplasia, 1.1% had advanced adenoma, and none had CRC.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenoma / epidemiology. Carcinoma in Situ / epidemiology. Colon / pathology. Colorectal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2006 Feb;101(2):263-5 [16454828.001]
  • (PMID = 16454827.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Yao K, Iwashita A, Tanabe H, Nishimata N, Nagahama T, Maki S, Takaki Y, Hirai F, Hisabe T, Nishimura T, Matsui T: White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow-band imaging: a new optical sign for differentiating between adenoma and carcinoma. Gastrointest Endosc; 2008 Sep;68(3):574-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow-band imaging: a new optical sign for differentiating between adenoma and carcinoma.
  • OBJECTIVE: To investigate whether the morphology of the WOS could be a useful optical sign for discriminating between adenoma and carcinoma.
  • MATERIALS: Forty-six gastric neoplasias of only 0-IIa type (18 adenomas and 28 early carcinomas) were evaluated.
  • INTERVENTION: The prevalence and the morphology of the WOS as visualized by ME with narrow-band imaging (NBI) according to histologic type (adenoma vs carcinoma).
  • MAIN OUTCOME MEASUREMENTS: The WOS is more frequently present in adenomas than in carcinomas.
  • With regard to the morphology of the WOS, 100% of the examples of WOS within adenomas demonstrated a regular distribution; in contrast, 83% of the examples of WOS within carcinomas showed an irregular distribution.
  • RESULTS: In cases in which a neoplasia of 0-IIa type showed either WOS with a regular distribution or a regular MVP, the sensitivity and specificity for discriminating adenoma from carcinoma were 94% and 96%, respectively.
  • CONCLUSION: In cases in which the WOS is observed, rather than assessing the MVP, morphologic analysis of the WOS could be an alternative new optical sign for discriminating adenoma from carcinoma when using ME with NBI.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Gastroscopy / methods. Radiographic Magnification. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2009 Aug;70(2):402; author reply 402-3 [19631809.001]
  • (PMID = 18656862.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Joniau S, Lerut E, Van Poppel H: A Giant Mucinous Adenocarcinoma Arising within a Villous Adenoma of the Urachus: Case Report and Review of the Literature. Case Rep Med; 2009;2009:818646
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Giant Mucinous Adenocarcinoma Arising within a Villous Adenoma of the Urachus: Case Report and Review of the Literature.
  • We present an exceptional case of a giant urachal tumor, consisting of both villous adenoma and mucinous adenocarcinoma of the urachus.
  • Initial transurethral biopsies showed only a villous adenoma of the urachus.
  • The indication for surgery was based on the typical imaging aspects, raising the suspicion of an underlying urachal adenocarcinoma (size and location).
  • Indeed, at final histopathology a concomitant well-differentiated adenocarcinoma of the urachus confined to the urachal mucosa was found.
  • Only three previous cases of urachal adenocarcinoma associated with villous adenoma have been described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1978 Feb;119(2):287-8 [633500.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] J Clin Pathol. 2003 Jun;56(6):465-7 [12783975.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] J Clin Pathol. 1993 May;46(5):450-2 [8320324.001]
  • [Cites] Changgeng Yi Xue Za Zhi. 1995 Sep;18(3):266-9 [8521338.001]
  • [Cites] Am J Clin Pathol. 1983 Jun;79(6):728-31 [6846264.001]
  • (PMID = 20182635.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2825668
  •  go-up   go-down


59. Kariya S, Kosaka M, Orita Y, Akagi H, Nishizaki K: Adenocarcinoma ex pleomorphic adenoma of the head and neck: Report of five cases. Auris Nasus Larynx; 2006 Mar;33(1):43-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma ex pleomorphic adenoma of the head and neck: Report of five cases.
  • OBJECTIVE: Adenocarcinoma ex pleomorphic adenoma is a rare tumor, and thus the management of the tumor has not been established.
  • RESULTS: We present five cases of adenocarcinoma ex pleomorphic adenoma of the head and neck, including a rare case with nasopharyngeal adenocarcinoma ex pleomorphic adenoma.
  • There was no response to chemotherapy with nedaplatin and 5-FU, but the nasopharyngeal adenocarcinoma ex pleomorphic adenoma showed a remarkable regression after the administration of docetaxel.
  • CONCLUSION: The combination therapy that includes docetaxel may be a promising treatment for adenocarcinoma ex pleomorphic adenoma of the head and neck.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Mouth Neoplasms / pathology. Nasopharyngeal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168590.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G: S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg Pathol; 2009 Jul;33(7):1031-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
  • Nephrogenic adenoma is a benign lesion that may occur at any site of the genitourinary tract, usually in association with previous urothelial injuries.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic adenocarcinoma, particularly with lesions arising in the prostatic urethra.
  • In this study, we investigated the expression of S100A1 and AMACR in 18 nephrogenic adenomas and in 100 prostatic adenocarcinomas.
  • A strong and distinct cytoplasmic or nucleocytoplasmic staining of S100A1 was found in 17 out of 18 cases of nephrogenic adenoma (94%), but never in prostatic adenocarcinoma.
  • In contrast, AMACR expression was detected in 14 of 18 nephrogenic adenomas (78%) and in 96 of 100 prostatic adenocarcinomas (96%).
  • We conclude that (1) S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from prostatic adenocarcinoma;.
  • (3) given that both S100A1 and AMACR have been reported to be expressed in renal tubular cells and in a subset of renal cell neoplasms, our findings confirm the histogenetic relationship between nephrogenic adenoma and renal tubular epithelium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Prostatic Neoplasms / diagnosis. S100 Proteins / biosynthesis. Urogenital Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384190.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / S100A1 protein; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


61. Nishio S, Tsuda H, Fujiyoshi N, Ota S, Ushijima K, Sasajima Y, Kasamatsu T, Kamura T, Matsubara O: Clinicopathological significance of cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia. Pathol Res Pract; 2009;205(5):331-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia.
  • However, LEGH has been associated with obvious cervical adenocarcinoma.
  • The clinicopathological significance of coexistence of LEGH with adenocarcinoma remains unclear.
  • We microscopically examined the presence or absence of LEGH components in 95 stage Ib cervical adenocarcinomas.
  • Gastric mucin was positive in all 16 LEGH components, as compared with only 6 of the 95 adenocarcinoma components.
  • Of the 16 adenocarcinomas with LEGH components, 15 were well-differentiated mucinous adenocarcinomas, and one was poorly differentiated adenocarcinoma.
  • Early cervical adenocarcinoma was relatively frequently associated with LEGH components.
  • LEGH may be one of the factors related to the development of cervical adenocarcinoma, but adenocarcinoma with LEGH components does not necessarily develop into a highly aggressive "adenoma malignum. "
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167836.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


62. Ferchichi L, Rammeh-Rommani S, Ben Hammouda S, Sfar R, Farah F, Ben Jilani S, Zermani R: [Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma]. Gynecol Obstet Fertil; 2006 May;34(5):410-2
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma].
  • The pathologic findings of the hysterectomy specimen with bilateral salpingoophorectomy showed an ovarian mucinous cystadenocarcinoma associated with an endometrioid adenocarcinoma of the uterine cervix.
  • In the literature, this tumor had been found in association with endocervical adenocarcinoma or with minimal deviation adenocarcinoma (adenoma malignum) of the uterine cervix.
  • However, its association with an endometrioid adenocarcinoma, to our knowledge, has not been reported.


63. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Moseley B, Mwirigi NW, Bowen J: Clostridium septicum Aortitis and Cecal Adenocarcinoma. Case Rep Med; 2010;2010:121728

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium septicum Aortitis and Cecal Adenocarcinoma.
  • We present a case of an 82-year-old male diagnosed with both C. septicum aortitis and a high-grade cecal tubulovillous adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Apr 1;67(7):1928-42 [2004306.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):30-7 [2642585.001]
  • [Cites] JAMA. 1969 Jul 21;209(3):385-8 [5819436.001]
  • [Cites] Radiology. 1980 Dec;137(3):625-7 [6934562.001]
  • [Cites] J Vasc Surg. 1996 Apr;23(4):714-8 [8627911.001]
  • [Cites] Tex Heart Inst J. 2009;36(4):334-6 [19693310.001]
  • [Cites] J Vasc Surg. 2001 Jan;33(1):106-13 [11137930.001]
  • [Cites] J Vasc Surg. 2003 Oct;38(4):847-51 [14560242.001]
  • [Cites] Ann Vasc Surg. 2006 Nov;20(6):825-9 [16773491.001]
  • [Cites] J Vasc Surg. 2009 May;49(5):1304-9 [19307090.001]
  • [Cites] Cardiovasc Surg. 1995 Dec;3(6):687-92 [8745194.001]
  • (PMID = 20224641.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2833300
  •  go-up   go-down


65. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study and review of polymorphous low-grade adenocarcinoma.
  • OBJECTIVES/HYPOTHESIS: We review a single institution's experience with polymorphous low-grade adenocarcinoma.
  • To our knowledge, this is the largest patient series of polymorphous low-grade adenocarcinoma with clinical follow-up in the otolaryngology literature.
  • STUDY DESIGN: We retrospectively identified 19 patients with polymorphous low-grade adenocarcinoma who had adequate clinical follow-up and pathologic specimens available for examination.
  • The most common initial diagnoses were polymorphous low-grade adenocarcinoma, adenoid cystic carcinoma, and pleomorphic adenoma.
  • CONCLUSIONS: Polymorphous low-grade adenocarcinoma is an increasingly recognized malignancy that originates predominantly in the minor salivary gland.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology


66. Vieth M, Stolte M: Elevated risk for gastric adenocarcinoma can be predicted from histomorphology. World J Gastroenterol; 2006 Oct 14;12(38):6109-14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated risk for gastric adenocarcinoma can be predicted from histomorphology.
  • This is valid both for first-degree relatives of gastric cancer patients and for patients with gastric adenoma and hyperplastic polyps.
  • In conclusion, corpus-dominant H pylori gastritis is significantly more common in patients with advanced and early gastric cancer, first-degree relatives of patients with gastric cancer, patients with gastric adenoma and gastric hyperplastic polyps.
  • [MeSH-major] Adenocarcinoma / etiology. Gastritis / pathology. Stomach / pathology. Stomach Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2001 Apr;7(2):243-7 [11819768.001]
  • [Cites] Tumour Biol. 1997;18(5):311-20 [9276031.001]
  • [Cites] Am J Gastroenterol. 1997 Dec;92(12):2220-4 [9399757.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):311-4 [9565339.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):263-6 [9683304.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Aug;12(8):735-40 [9726386.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Oct;13(10):1050-7 [9835323.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Jul;11(7):717-20 [10445789.001]
  • [Cites] Cancer. 1958 Nov-Dec;11(6):1149-55 [13608416.001]
  • [Cites] World J Gastroenterol. 2005 Feb 14;11(6):791-6 [15682469.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):976-81 [15742399.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):857-69 [16338646.001]
  • [Cites] Gut. 2000 May;46(5):639-44 [10764706.001]
  • [Cites] Gastroenterol Clin North Am. 2000 Dec;29(4):819-27 [11190066.001]
  • [Cites] Virchows Arch. 2000 Dec;437(6):581-90 [11193468.001]
  • [Cites] Digestion. 2001;64(1):30-9 [11549834.001]
  • [Cites] World J Gastroenterol. 2001 Apr;7(2):248-53 [11819769.001]
  • [Cites] Dig Dis Sci. 2002 Jun;47(6):1248-56 [12064799.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):770-3 [12354805.001]
  • [Cites] Helicobacter. 2003 Feb;8(1):29-35 [12603614.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):317-21 [12715167.001]
  • [Cites] JAMA. 2004 Jan 14;291(2):187-94 [14722144.001]
  • [Cites] J Gastroenterol. 2004;39(4):324-8 [15168242.001]
  • [Cites] Eur J Cancer Prev. 2004 Oct;13(5):457-9 [15452460.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1183-8 [15489580.001]
  • [Cites] Endoscopy. 1983 Jan;15(1):8-11 [6822229.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1528-34 [2418943.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3554-60 [3288329.001]
  • [Cites] J Clin Pathol. 1989 Aug;42(8):834-9 [2768523.001]
  • [Cites] Z Gastroenterol. 1990 May;28(5):229-33 [2402931.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):2047-51 [2224804.001]
  • [Cites] Cancer Causes Control. 1991 Jul;2(4):227-33 [1873452.001]
  • [Cites] Gut. 1992 Apr;33(4):429-31 [1582581.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):50-5 [1606546.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(6):489-98 [1609509.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1727-31 [1516027.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1841-5 [8364862.001]
  • [Cites] Zentralbl Bakteriol. 1993 Sep;280(1-2):137-43 [8280935.001]
  • [Cites] Scand J Gastroenterol Suppl. 1994;201:28-34 [8047821.001]
  • [Cites] Virchows Arch. 1994;425(4):339-47 [7820298.001]
  • [Cites] Gut. 1995 Jan;36(1):12-6 [7890214.001]
  • [Cites] Z Gastroenterol. 1995 Feb;33(2):89-93 [7725762.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1995 May;7(5):461-5 [7614109.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] Virchows Arch. 1997 Jul;431(1):11-5 [9247628.001]
  • (PMID = 17036380.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 47
  • [Other-IDs] NLM/ PMC4088102
  •  go-up   go-down


67. Ahn JY, Chang JH, Kim SH, Lee KS: Pleomorphic adenocarcinoma of the lacrimal gland with multiple intracranial and spinal metastases. World J Surg Oncol; 2007;5:29
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenocarcinoma of the lacrimal gland with multiple intracranial and spinal metastases.
  • BACKGROUND: Pleomorphic adenoma of the lacrimal gland is known to undergo malignant transformation when incompletely excised.
  • CASE PRESENTATION: A 50-year-old woman presented with malignant transformation associated with both intracranial invasion and multiple intracranial and spinal disseminations in the third recurrence of pleomorphic adenoma of the lacrimal gland, 6 years after initial treatment.
  • CONCLUSION: It is important to recognize that leptomeningeal intracranial and spinal disseminations of pleomorphic adenocarcinoma can occur, although it is extremely rare.
  • To our knowledge, we report the first case of pleomorphic adenocarcinoma of the lacrimal gland presumably metastasizing to the intracranium and spine.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1981 Dec;54(648):1034-8 [7296228.001]
  • [Cites] Am J Surg. 1984 Oct;148(4):539-41 [6486324.001]
  • [Cites] Radiother Oncol. 1987 Jul;9(3):175-83 [2819957.001]
  • [Cites] Int Ophthalmol Clin. 1982 Spring;22(1):99-120 [6277818.001]
  • [Cites] Ophthalmology. 1989 Apr;96(4):431-5 [2726173.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Dec;30(13):1038-42 [1714052.001]
  • [Cites] Am J Ophthalmol. 1970 Nov;70(5):767-70 [4097730.001]
  • [Cites] Am J Ophthalmol. 1971 Jan;71(1 Pt 2):178-92 [5542123.001]
  • [Cites] Cancer. 1980 May 15;45(10):2593-2606 [7378993.001]
  • [Cites] Ophthalmology. 1980 Jun;87(6):466-75 [7413135.001]
  • [Cites] Arch Ophthalmol. 1998 May;116(5):613-6 [9596497.001]
  • [Cites] Ann Ophthalmol. 1993 Nov;25(11):422-6 [8109884.001]
  • [Cites] Int Ophthalmol Clin. 1993 Summer;33(3):181-8 [8407184.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):401-7 [1320924.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):395-400 [1320923.001]
  • (PMID = 17341319.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1820784
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


68. Andreu Garcia M: [Esophageal adenoma-carcinoma and Barrett's esophagus. Gastric adenocarcinoma and Helicobacter pylori]. Gastroenterol Hepatol; 2008 Oct;31 Suppl 4:66-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Esophageal adenoma-carcinoma and Barrett's esophagus. Gastric adenocarcinoma and Helicobacter pylori].
  • [Transliterated title] Adenocarcinoma esfágico y esófago de Barrett. Adenocarcinoma gástrico y Helicobacter pylori.
  • In the last two decades, the incidence of esophageal cancer has progressively increased, especially that of adenocarcinomas localized in the esophagogastric junction.
  • In the meeting of the American Gastroenterological Association, notable among all the studies presented on the prevention and treatment of esophageal and gastric cancer were the following contributions: the use of clinical practice guidelines for the prevention and surveillance of Barrett's esophagus (BE) should be improved; treatment with proton pump inhibitors does not seem to reduce the risk of esophageal cancer; endoscopic therapy of intramucosal cancer through complete mucosal resection is effective; Helicobacter pylori eradication prevents the development of metachronous gastric cancer in patients treated for a first intramucosal adenocarcinoma through endoscopic resection; the risk of developing gastric cancer is 6 times higher in patients with mucosa-associated lymphoid tissue (MALT) lymphoma than in the general population; and photodynamic therapy may be an alternative for the treatment of "invisible" gastric adenocarcinoma, which should be followed-up endoscopically.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / etiology


69. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Feb;16(2):297-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.
  • We investigated leptin expression in normal and neoplastic colorectal tissues and its association with clinicopathological features and clinical outcome in colorectal adenocarcinoma patients.
  • Leptin expression was evaluated on the tissue microarray of 44 normal colon mucosal tissues, 44 adenomatous polyps, and 437 colorectal adenocarcinomas by immunohistochemistry.
  • Frequency of leptin expression was dramatically increased from normal colonic mucosa (2/44, 4.5%) to adenomas (13/44, 29.5%) and adenocarcinomas (321/437, 73.5%) as neoplastic progression.
  • In univariate survival analysis, patients with leptin-positive adenocarcinoma revealed better overall and disease-free survivals (p = 0.032 and p = 0.004, respectively, log-rank test).
  • We conclude that leptin was gradually expressed during the normal-adenoma-adenocarcinoma sequence, suggesting an association in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Leptin / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Colon / metabolism. Colon / pathology. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Phenotype. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050975.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


70. Lazarev AF, Kobiakov DS, Klimachev VV, Avdalian AM, Bobrov IP: [Argyrophilic nucleolar organizer region associated proteins in adenomas with varying colonic dysplasia and adenocarcinoma]. Arkh Patol; 2010 Jul-Aug;72(4):16-20
Hazardous Substances Data Bank. SILVER NITRATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Argyrophilic nucleolar organizer region associated proteins in adenomas with varying colonic dysplasia and adenocarcinoma].
  • There were statistically significant differences in the quantity, area, area index of Ag-NOR proteins between the groups: the mucosa (lower 2/3 crypts), mild, moderate, and severe dysplasia of adenoma.
  • Only the estimation of the area index of Ag-NOR proteins indicated statistically significant differences between severe dysplasia and highly differentiated adenocarcinoma.
  • Colonic adenomas showed a correlation of the activity of Ag-NOR proteins with epithelial dysplasia, but no correlation with the size and histological type of their structure.
  • [MeSH-major] Adenocarcinoma. Adenoma. Antigens, Nuclear / metabolism. Colonic Neoplasms. Intestinal Mucosa

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086631.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins; 95IT3W8JZE / Silver Nitrate
  •  go-up   go-down


71. Tarakji B, Nassani MZ, Sloan P: Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. Med Oral Patol Oral Cir Bucal; 2010 May;15(3):e432-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types.
  • OBJECTIVE: Our study aimed to characterize alteration in the immunohistochemical expression of oestrogens receptor and progesterone receptor in the tumour cells of carcinoma arising in pleomorphic adenoma.
  • STUDY DESIGN: 27 cases of carcinoma arising in pleomorphic adenoma (undifferentiated and adenocarcinoma types) were examined.
  • CONCLUSION: Our data suggest that carcinomas arising in pleomorphic adenoma were not dependent on endocrine function.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Neoplasms, Multiple Primary / metabolism. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Salivary Gland Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038908.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


72. Kohno T, Kunitoh H, Suzuki K, Yamamoto S, Kuchiba A, Matsuno Y, Yanagitani N, Yokota J: Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias. Carcinogenesis; 2008 May;29(5):957-63
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias.
  • The pulmonary adenoma susceptibility 1 (Pas1) gene affects susceptibility to the development of lung adenomas in mice with a subset of the adenomas progressing to adenocarcinoma (ADC).
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic. Polymorphism, Single Nucleotide. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299280.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Nuclear; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / PASD1 protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


73. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B, Meijer GA: MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer; 2009 Aug 18;101(4):707-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression.
  • In colorectal tumours, the combination of gain of 8q and 13q is one of the major factors associated with colorectal adenoma to adenocarcinoma progression.
  • We investigated the contribution of the miR-17-92 cluster during colorectal adenoma to adenocarcinoma progression.
  • CONCLUSION: Increased expression of miR-17-92 cluster during colorectal adenoma to adenocarcinoma progression is associated to DNA copy number gain of miR17-92 locus on 13q31 and c-myc expression.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Chromosomes, Human, Pair 13 / genetics. Colorectal Neoplasms / genetics. MicroRNAs / genetics. Proto-Oncogene Proteins c-myc / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cell. 1993 Dec 3;75(5):855-62 [8252622.001]
  • [Cites] J Clin Pathol. 1998 Dec;51(12):901-9 [10070331.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Nature. 2005 Dec 1;438(7068):685-9 [16258535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92 [16505370.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • [Cites] Mol Cancer. 2006;5:29 [16854228.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2135-43 [17135249.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2130-4 [17135268.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1424-9 [17308079.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):410-2 [17325905.001]
  • [Cites] Cell. 2007 Apr 20;129(2):303-17 [17397913.001]
  • [Cites] Blood. 2007 May 15;109(10):4399-405 [17284533.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1482-90 [17608773.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):272-86 [18328430.001]
  • [Cites] Cell. 2008 Mar 7;132(5):860-74 [18329371.001]
  • [Cites] Cell. 2008 Mar 7;132(5):875-86 [18329372.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2167-74 [18212054.001]
  • [Cites] Nat Immunol. 2008 Apr;9(4):405-14 [18327259.001]
  • [Cites] Cell. 2008 Apr 18;133(2):217-22 [18423194.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1134-8 [11861394.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1109-19 [12360473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • (PMID = 19672269.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN17 microRNA, human; 0 / MYC protein, human; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ PMC2736819
  •  go-up   go-down


74. Wu CC, Shyu RY, Chou JM, Jao SW, Chao PC, Kang JC, Wu ST, Huang SL, Jiang SY: RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. Eur J Cancer; 2006 Mar;42(4):557-65
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma.
  • This study investigated the clinical significance of RARRES1 protein and its association with RARRES3 protein expression in 161 (26 adenoma, 13 distal normal mucosa and 122 primary colorectal adenocarcinoma) paraffin-embedded colorectal tissues by immunohistochemistry.
  • RARRES1 protein was detected at the highest levels in terminally differentiated cells of normal mucosal tissues and all 26 adenoma tissues.
  • Among 122 colorectal adenocarcinomas, the poorly differentiated adenocarcinomas and Dukes' stage D tumours showed a significant decrease in RARRES1 expression (P < 0.001 and P < 0.01, respectively).
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / metabolism. Colorectal Neoplasms / pathology. Membrane Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426842.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RARRES1 protein, human; 0 / RARRES3 protein, human; 0 / Receptors, Retinoic Acid
  •  go-up   go-down


75. Wada R: Proposal of a new hypothesis on the development of colorectal epithelial neoplasia: nonspecific inflammation--colorectal Paneth cell metaplasia--colorectal epithelial neoplasia. Digestion; 2009;79 Suppl 1:9-12
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal epithelial neoplasia (CR-EN), both adenoma and adenocarcinoma, may develop from the essential tubules of the colorectum.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Paneth Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153484.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


76. Turrini R, Lanzani G, Salmi A: [Gallbladder adenoma with focal adenocarcinoma: a case report]. Recenti Prog Med; 2007 Oct;98(10):506-8
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gallbladder adenoma with focal adenocarcinoma: a case report].
  • [Transliterated title] Adenoma con focale adenocarcinoma della colecisti: descrizione di un caso.
  • Video-laparoscopic cholecystectomy was performed, and histological examination of the lesion revealed a severely dysplastic tubular adenoma and chronic cholecystitis.
  • [MeSH-major] Adenoma / diagnosis. Cholecystectomy, Laparoscopic. Gallbladder Neoplasms / diagnosis. Polyps / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970176.001).
  • [ISSN] 0034-1193
  • [Journal-full-title] Recenti progressi in medicina
  • [ISO-abbreviation] Recenti Prog Med
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


77. Chaâbouni S, Ayadi L, Dhouib H, Abbès K, Khabir A, Boudawara T: [Polymorphous low-grade adenocarcinoma: a palatine and a labial location]. Rev Stomatol Chir Maxillofac; 2008 Jun;109(3):178-82
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polymorphous low-grade adenocarcinoma: a palatine and a labial location].
  • INTRODUCTION: Polymorphous low-grade adenocarcinoma (PLGA) is a variant of malignant tumor of minor salivary glands.
  • Biopsy was positive for a pleomorphic adenoma.
  • DISCUSSION: The morphologic diversity and cytological uniformity of PLGA may make the differential diagnostic difficult especially with adenoid cystic carcinoma and pleomorphic adenoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lip Neoplasms / diagnosis. Palatal Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Aged. Biopsy. Carcinoma, Adenoid Cystic / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18534647.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


78. Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, Nomoto K, Takano Y: Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors. Anticancer Res; 2007 Jan-Feb;27(1A):259-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors.
  • This study aimed to explore the roles of maspin expression in the tumorigenesis and progression of colorectal adenocarcinoma (CRA).
  • MATERIALS AND METHODS: Maspin expression was examined on tissue microarrays containing CRAs (n = 119), adjacent adenoma (n = 22), adjacent non-cancerous mucosa (n = 118) and metastases (n = 67) by immunostaining.
  • RESULTS: Maspin expression showed significant increase from colorectal non-cancerous mucosa to adenocarcinoma through adenoma (p < 0.05).
  • CONCLUSION: Up-regulated maspin expression was involved in colorectal adenoma-adenocarcinoma sequence.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Liver Neoplasms / secondary. Serpins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352241.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / SERPIN-B5; 0 / Serpins; 0 / Tenascin
  •  go-up   go-down


79. Kang HJ, Park DY, Kim KH, Song GA, Lauwers GY: [Pathologic diagnosis of gastric epithelial neoplasia]. Korean J Gastroenterol; 2008 Nov;52(5):273-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric epithelial neoplasia is a very common disease entity in Korea, encompassing gastric adenoma and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Stomach Neoplasms / pathology. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077472.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 25
  •  go-up   go-down


80. Osunkoya AO, Epstein JI: Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol; 2007 Sep;31(9):1323-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
  • Prostatic urothelial-type adenocarcinoma arises through a process of glandular metaplasia of the prostatic urethral urothelium and subsequent in situ adenocarcinoma sometimes associated with villous adenoma.
  • These prostatic adenocarcinomas are analogous to nonurachal adenocarcinomas arising in the bladder from cystitis glandularis.
  • Only 2 cases of urothelial-type adenocarcinoma from an institution other than our own have been previously described.
  • The distinction between adenocarcinoma from another organ secondarily involving the prostate, usual adenocarcinoma of the prostate, and prostatic urothelial-type adenocarcinoma can present a significant diagnostic challenge and has significant therapeutic implications.
  • Fifteen cases of prostatic urothelial-type adenocarcinoma were retrieved from the consult files of one of the authors.
  • In 8/15 (53%) cases, glandular metaplasia of the prostatic urethra and contiguous transition to adenocarcinoma were identified.
  • Prostatic urothelial-type adenocarcinoma is a rare aggressive cancer arising in the prostate.
  • The differential diagnosis includes conventional prostatic mucinous adenocarcinoma and secondary infiltration from a colonic or bladder adenocarcinoma.
  • Immunohistochemistry for prostate specific antigen, prostate specific acid phosphatase, and high molecular weight cytokeratin along with morphology can help rule out conventional prostate carcinoma. beta-catenin, CDX2, and clinical studies are needed to rule out colonic adenocarcinoma.
  • As prostatic urothelial-type adenocarcinoma is entirely analogous to bladder adenocarcinoma in both, its morphology and immunophenotype, only clinical studies or in some cases pathologic examination of the cystoprostatectomy specimen can exclude infiltration from a primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Mucins / analysis. Prostatic Neoplasms / diagnosis. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721186.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucins; 0 / beta Catenin; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


81. Jung JT, Lee CH, You SS, Ha HK, Bae JS, Kwon JG, Kim EY, Kim HG, Cho CH, Shin IH: [Grading of histology, expression of apoptosis and cell proliferation in gastric mucosa adjacent to gastric adenoma or adenocarcinoma]. Korean J Gastroenterol; 2005 Oct;46(4):269-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Grading of histology, expression of apoptosis and cell proliferation in gastric mucosa adjacent to gastric adenoma or adenocarcinoma].
  • BACKGROUND/AIMS: Helicobacter pylori (H. pylori) infection can lead to gastric adenoma and carcinoma through atrophic gastritis and intestinal metaplasia.
  • METHODS: Endoscopically diagnosed twenty cases of intestinal type gastric carcinoma, 20 cases of gastric adenoma, and 40 cases of control (normal or gastritis) were enrolled. H. pylori infection rate, histologic grading, apoptosis and immunohistochemical stain (Ki-67 and p53) to check mucosal proliferation were done in endoscopically biopsied tissues at antrum and body at least 2 cm apart from adenoma or carcinoma.
  • In the multivariate analysis, only atrophy of gland was a significant risk factor for adenoma compared to control group (OR 3.7).
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Apoptosis. Cell Proliferation. Gastric Mucosa / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247270.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


82. McCluggage WG, Harley I, Houghton JP, Geyer FC, MacKay A, Reis-Filho JS: Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome. J Clin Pathol; 2010 Oct;63(10):935-41
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome.
  • An unusual cervical adenocarcinoma is reported in a 50-year-old woman with a history of Peutz Jeghers syndrome.
  • The carcinoma contained two morphologically distinct and spatially separate components, one comprising typical well differentiated adenoma malignum and the other a moderately differentiated neoplasm, in keeping with gastric type adenocarcinoma.
  • It is believed that the component of gastric type adenocarcinoma arose through a process of dedifferentiation within adenoma malignum and we provide circumstantial molecular evidence in support of the interpretation that both components may be clonally related in that they displayed an extra copy of chromosome 7.
  • This raises the possibility of a relationship between these two uncommon types of cervical adenocarcinoma, both of which are thought to exhibit gastric differentiation.
  • [MeSH-major] Adenocarcinoma / pathology. Mixed Tumor, Malignant / pathology. Peutz-Jeghers Syndrome / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876329.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Sun W, Iijima T, Kano J, Kobayashi H, Li D, Morishita Y, Okubo C, Anami Y, Noguchi M: Frequent aberrant methylation of the promoter region of sterile alpha motif domain 14 in pulmonary adenocarcinoma. Cancer Sci; 2008 Nov;99(11):2177-84
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent aberrant methylation of the promoter region of sterile alpha motif domain 14 in pulmonary adenocarcinoma.
  • In order to identify novel hypermethylated genes in early stage lung adenocarcinoma, we carried out methylated CpG island amplification, modified suppression subtractive hybridization, and methylation-specific polymerase chain reaction to identify aberrant methylation of CpG islands in the A/J mouse lung adenoma model, which histologically mimics the early stage of human pulmonary adenocarcinoma.
  • Two of them showed downregulation of their expression in human lung adenocarcinoma.
  • Most of the lung adenocarcinoma cell lines showed suppressed expression of SAMD14 together with hypermethylation at the promoter region, although an immortalized bronchial epithelium cell line (PL16B) did not show hypermethylation and did express SAMD14.
  • Hypermethylation at the CpG site of the SAMD14 promoter region was detected frequently in early invasive adenocarcinoma (8/24, 33.3%) but not in in situ adenocarcinoma (0/7, 0%) or normal lung tissue (0/31, 0%).
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Lung Neoplasms / genetics. Promoter Regions, Genetic / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18823374.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KIF21A protein, human; 0 / Kif21a protein, mouse; 0 / Tumor Suppressor Proteins; EC 3.6.1.- / Kinesin
  •  go-up   go-down


84. Herawi M, Drew PA, Pan CC, Epstein JI: Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. Hum Pathol; 2010 Apr;41(4):594-601
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma.
  • Although clear cell adenocarcinoma have been described focally mimicking nephrogenic adenoma, we have identified a subset of clear cell adenocarcinoma that diffusely resembles nephrogenic adenoma (nephrogenic adenoma-like clear cell adenocarcinoma).
  • Twelve classic clear cell adenocarcinomas of the bladder and urethra and 7 nephrogenic adenoma-like clear cell adenocarcinomas were compared to 10 nephrogenic adenomas.
  • Classic clear cell adenocarcinomas and nephrogenic adenoma-like clear cell adenocarcinomas comprised 4 men and 15 women.
  • The following features were seen in classic clear cell adenocarcinomas: nephrogenic adenoma-like clear cell adenocarcinomas: predominantly solid pattern (7/12:0/7), marked nuclear pleomorphism (7/12:1/7), prominent nucleoli (5/12:1/7), clear cytoplasm in 50% or greater of tumor (7/12:0/7), and necrosis (8/12:3/7), although the necrosis in nephrogenic adenoma-like clear cell adenocarcinomas was often focal and intraluminal.
  • Both patterns of clear cell adenocarcinomas showed prominent hobnail features, although more pronounced in nephrogenic adenoma-like clear cell adenocarcinomas.
  • Muscularis propria invasion was seen in 5 of 9 classic clear cell adenocarcinomas and 6 of 6 nephrogenic adenoma-like clear cell adenocarcinomas, where evaluable.
  • Classic clear cell adenocarcinoma was associated with urothelial carcinoma (n = 2) and endometriosis (n = 1).
  • The Ki-67 rate in clear cell adenocarcinomas ranged from 10% to 80% compared with 0% to 5% in nephrogenic adenoma.
  • The following antibodies were not helpful in distinguishing nephrogenic adenoma-like clear cell adenocarcinoma from nephrogenic adenoma: CD10, estrogen receptor, p63, high-molecular-weight cytokeratin, and alpha-methylacyl coenzyme-A racemase.
  • PAX2 expression was more frequent in nephrogenic adenoma (89%) compared to both patterns of clear cell adenocarcinoma (29%-32%).
  • The key features discriminating between nephrogenic adenoma-like clear cell adenocarcinoma and nephrogenic adenoma include occasional clear cells, more prominent pleomorphism especially hyperchromatic enlarged nuclei, and extensive muscular invasion.
  • Presence of mitoses and a high rate of Ki-67 expression in lesions resembling nephrogenic adenoma require clinical correlation, close follow-up, and repeat biopsy with more extensive sampling.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma / diagnosis. Urethral Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc.
  • (PMID = 20060152.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol; 2005 Aug;58(8):833-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
  • AIMS: To examine the relation between p-STAT3 (activated form of STAT3) expression and clinicopathological factors in human colorectal adenocarcinoma and adenoma.
  • METHODS: Immunohistochemical analyses were carried out on tissues from 44 colorectal adenomas and 95 colorectal adenocarcinomas, comprising 18 intramucosal carcinomas and 77 invasive carcinomas.
  • Only eight of the 44 adenomas showed immunopositivity for p-STAT3, resulting in a significant difference between total adenocarcinomas and adenomas (p < 0.001).
  • Among the 95 cases of colorectal adenocarcinoma, p-STAT3 immunoreactivity was significantly correlated with the depth of tumour invasion (p < 0.05), venous invasion (p < 0.05), lymph node metastasis (p < 0.05), and increasing stages of the Dukes' classification (p < 0.01).
  • These findings suggest that p-STAT3 expression is an important factor related to carcinogenesis and/or tumour invasion of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 Apr 15;73(8):2076-82 [8156513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4806-10 [7545930.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1285-90 [7992833.001]
  • [Cites] Cancer Lett. 2000 Apr 3;151(1):31-8 [10766420.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2607-11 [10851059.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):67-73 [11006034.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):230-41 [11281168.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] Cancer. 2002 May 1;94(9):2393-400 [12015764.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1517-27 [12629515.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):891-905 [12949733.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):209-22 [14603523.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):15114-23 [14701810.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3550-60 [15116091.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1569-73 [15162527.001]
  • [Cites] Br J Surg. 1976 May;63(5):384-8 [1268479.001]
  • [Cites] Histopathology. 1981 Mar;5(2):141-63 [7216178.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1340-5 [3742458.001]
  • [Cites] Science. 1994 Apr 1;264(5155):95-8 [8140422.001]
  • [Cites] Cytokine. 1995 Feb;7(2):118-29 [7780031.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):591-4 [7566171.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3651-8 [8670868.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):600-4 [9263538.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):433-42 [9711905.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):326-30 [9766567.001]
  • [Cites] J Leukoc Biol. 1998 Nov;64(5):675-80 [9823774.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Jpn J Cancer Res. 1998 Dec;89(12):1267-75 [10081487.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] J Clin Pathol. 1949 May;2(2):95-8 [16810849.001]
  • (PMID = 16049285.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC1770863
  •  go-up   go-down


86. Schmidt D, Horn LC, Kommoss F: [Histopathology of squamous cell carcinoma and adenocarcinoma of the uterine cervix]. Pathologe; 2005 Jul;26(4):255-61
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathology of squamous cell carcinoma and adenocarcinoma of the uterine cervix].
  • Adenocarcinomas are much more infrequent.
  • Among the various forms of adenocarcinoma, the mucinous subtype is the most frequent, either as endocervical or interstinal subtype.
  • Great concern in daily diagnosis causes the adenoma malignum (minimal deviation adenocarcinoma), since this type of adenocarcinoma demonstrates only minor cytological atypia and greatly resembles the different types of endocervical glandular hyperplasia.A report on a cervical carcinoma should always include the typing and grading of the tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):327-46 [12352182.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1540-5 [11717545.001]
  • [Cites] Int J Gynecol Pathol. 2002 Apr;21(2):125-33 [11917221.001]
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):345-8 [10600287.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):7-43 [11385777.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Feb;64(2):201-5 [8820003.001]
  • [Cites] Am J Surg Pathol. 1985 Dec;9(12):883-9 [3934992.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1158-71 [7573674.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jul;12(3):264-9 [7688354.001]
  • [Cites] Int J Epidemiol. 1988 Sep;17(3):501-8 [3209326.001]
  • [Cites] Zentralbl Gynakol. 2001 May;123(5):255-65 [11449618.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Dec;87(2):183-9 [10597972.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):915-21 [9255254.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2471-83 [11745305.001]
  • (PMID = 15915328.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Colvin M, Delis A, Bracamonte E, Villar H, Leon LR Jr: Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal. World J Gastroenterol; 2009 Jul 28;15(28):3560-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal.
  • In particular, adenomas and adenocarcinomas are distinctly rare entities in this region.
  • We describe an infiltrating, well-differentiated adenocarcinoma arising in a villous adenoma from the distal anal canal, in an otherwise healthy patient at low risk for gastrointestinal malignancy.
  • Microscopic evaluation revealed an infiltrating well-differentiated adenocarcinoma, arising from a villous adenoma.
  • Our report is the first describing the possible malignant degeneration of a villous adenoma in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Anal Canal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2000 Aug;66(8):789-92 [10966042.001]
  • [Cites] Colorectal Dis. 2008 Jul;10(6):621-3 [17949443.001]
  • [Cites] Histopathology. 2002 Mar;40(3):302-4 [11895502.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1320-4 [14530668.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):249-62 [15137955.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1780-1 [16586552.001]
  • [Cites] Colorectal Dis. 2006 May;8(4):296-301 [16630233.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):576-8 [17101482.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7304-8 [17143945.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1977-9 [17212165.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] Surg Today. 2007;37(7):596-9 [17593481.001]
  • [Cites] Tech Coloproctol. 2007 Dec;11(4):340-2 [18060528.001]
  • [Cites] J Am Osteopath Assoc. 2001 Aug;101(8):450-3 [11526879.001]
  • (PMID = 19630115.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2715986
  •  go-up   go-down


88. Kushima R, Vieth M, Borchard F, Stolte M, Mukaisho K, Hattori T: Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach. Gastric Cancer; 2006;9(3):177-84
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach.
  • Since 1985, when gastric-type well-differentiated adenocarcinomas were demonstrated in hyperplastic polyps of the stomach, we have studied phenotypic expression in gastrointestinal epithelial lesions.
  • The disease entity of gastric-type well-differentiated adenocarcinoma has recently been accepted, especially in Japan and Europe.
  • Even under these circumstances, the term "gastric adenoma" usually means flat adenoma of the intestinal type.
  • Gastric-type adenomas have been regarded as exceptional until recently.
  • Although gastric-type adenomas could theoretically be classified into foveolar type and pyloric-gland type, foveolar-type adenoma is, in practice, difficult to distinguish from gastric-foveolar-type adenocarcinoma.
  • In 2003, we first reported systematic clinicopathological analyses of pyloric gland adenoma, demonstrating its unstable and precancerous nature.
  • In this article, we review and discuss the clinicopathological and molecular pathological aspects of gastric-type well-differentiated adenocarcinomas and pyloric gland adenomas, mainly based on our published and unpublished data.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Gastric Mucosa / pathology. Stomach Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Pathologe. 2001 Jan;22(1):44-55 [11225445.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):786-95 [12920223.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):854-60 [15533229.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1995 Apr;92(4):761-8 [7739127.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):77-82 [9916921.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):737-40 [11920644.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Pathol. 1985 Jun;38(6):622-30 [4008664.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18327-36 [11278439.001]
  • [Cites] Virchows Arch. 2005 May;446(5):542-5 [15838648.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):317-21 [12715167.001]
  • [Cites] Virchows Arch. 2002 Feb;440(2):205-8 [11964052.001]
  • [Cites] Virchows Arch. 2005 May;446(5):537-41 [15838649.001]
  • [Cites] Acta Pathol Jpn. 1982;32 Suppl 2:329-47 [6765003.001]
  • [Cites] Virchows Arch. 1999 Oct;435(4):452-7 [10526011.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1276-85 [12360042.001]
  • [Cites] Pathol Int. 1996 Nov;46(11):908-17 [8970203.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):103-11 [7903667.001]
  • [Cites] Verh Dtsch Ges Pathol. 2000;84:50-61 [11217449.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Crit Rev Oncol Hematol. 1994 Dec;17(3):153-80 [7865137.001]
  • [Cites] J Natl Cancer Inst. 1991 May 1;83(9):640-3 [2023282.001]
  • [Cites] Pathol Res Pract. 1996 Sep;192(9):963-9; discussion 970-1 [8950764.001]
  • (PMID = 16952035.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 42
  •  go-up   go-down


89. Lemyé AC, Guy-Viterbo V, van Vyve E: Adenocarcinoma of the duodenum arising in a tubulo-villous adenoma. Acta Chir Belg; 2009 Jan-Feb;109(1):95-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the duodenum arising in a tubulo-villous adenoma.
  • Villous adenoma of the duodenum is rare and has a high prevalence of cancer.
  • We report here an unusual case of a 73-year-old man who presented with a tumour on the second part of the duodenum with moderate dysplasia of a tubulo-villous adenoma at the biopsies.
  • The final histological analysis was a moderately differentiated invasive duodenal adenocarcinoma (pT3Nx).
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Duodenal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19341205.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


90. Devesa SS, Bray F, Vizcaino AP, Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer; 2005 Nov 1;117(2):294-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.
  • Most lung cancers are squamous cell carcinoma, small cell carcinoma, or adenocarcinoma; trends vary according to type.
  • In contrast, adenocarcinoma rates rose among males and females in virtually all areas, with the increases among males exceeding 50% in many areas of Europe; among females, rates also rose rapidly and more than doubled in Norway, Italy and France.
  • Rates of all lung cancer types among women and adenocarcinoma among men continue to rise despite declining cigarette use in many Western countries and shifts to filtered/low-tar cigarettes.
  • [MeSH-major] Adenoma / epidemiology. Lung Neoplasms / classification. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Europe / epidemiology. Female. Humans. Incidence. Male. North America / epidemiology. Prevalence. Sex Characteristics

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900604.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Shah SS, Adelson M, Mazur MT: Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases. Int J Gynecol Pathol; 2008 Jul;27(3):453-6
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases.
  • Adenocarcinoma in situ rarely occurs in vulvar papillary hidradenoma.
  • We encountered 2 cases of adenocarcinoma in situ arising in a papillary hidradenoma of the vulva.
  • On microscopic examination, the tumors showed focal features of benign hidradenoma at the periphery with transitions into areas of increasing cytologic atypia that fulfilled criteria for adenocarcinoma in situ similar to that seen in the breast.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Carcinoma in Situ / pathology. Vulvar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580327.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


93. Ishida M, Egawa S, Sakata N, Mikami Y, Motoi F, Abe T, Fukuyama S, Sunamura M, Furukawa T, Unno M: Intraductal papillary-mucinous adenocarcinoma in the remnant pancreas after pancreatoduodenectomy for cancer of Vater's papilla associated with intraductal papillary-mucinous adenoma. J Hepatobiliary Pancreat Surg; 2007;14(5):522-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous adenocarcinoma in the remnant pancreas after pancreatoduodenectomy for cancer of Vater's papilla associated with intraductal papillary-mucinous adenoma.
  • A 72-year-old woman, who had undergone pylorus-preserving pancreatoduodenectomy 3 years before for cancer of Vater's papilla associated with a branch-type intraductal papillary-mucinous adenoma (IPMA), developed dilatation of the main duct and a nodular lesion in the remnant pancreas.
  • Total pancreatectomy was performed, which revealed that the lesion was intraductal papillary-mucinous adenocarcinoma (IPMC) with minimal invasion, suggesting the metachronous multicentric occurrence of this intraductal papillary-mucinous neoplasm (IPMN).
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Ampulla of Vater. Carcinoma, Pancreatic Ductal / diagnosis. Common Bile Duct Neoplasms / surgery. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909725.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. Fancher TT, Dudrick SJ, Palesty JA: Papillary adenocarcinoma of the urachus presenting as an umbilical mass. Conn Med; 2010 Jun-Jul;74(6):325-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the urachus presenting as an umbilical mass.
  • The patient subsequently underwent a cystoscopic biopsy which was positive for papillary adenocarcinoma arising in a villous adenoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Urachus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20648839.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, Na W, Lee KH, Choi D, Jang SJ: Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol; 2007 Dec;14(12):3453-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
  • We investigated the expression of Apaf-1 in colorectal tissues corresponding to the multistep carcinogenesis model to determine correlations between the clinicopathologic characteristics and the expression of this molecule and to evaluate the role of Apaf-1 in the development and progression of colorectal adenocarcinoma.
  • METHODS: Immunohistochemistry for Apaf-1 was performed on the tissue microarray of 38 normal mucosal tissues, 46 adenomatous polyps, 529 colorectal adenocarcinomas, and 76 metastatic tumors.
  • RESULTS: Normal colonic mucosa tissues and adenomas were positive for Apaf-1 with no exceptions (100%).
  • However, in colorectal adenocarcinomas, 119 of 529 cases (22.5%) were positive and 410 cases (77.5%) were negative.
  • CONCLUSIONS: The results suggest that the loss of Apaf-1 expression is a relatively frequent late event and the loss of Apaf-1 expression may play an important role in tumorigenesis and tumor progression in colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882496.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor
  •  go-up   go-down


96. Kassie F, Kalscheuer S, Matise I, Ma L, Melkamu T, Upadhyaya P, Hecht SS: Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice. Carcinogenesis; 2010 Feb;31(2):239-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice.
  • In previous studies, we reported that indole-3-carbinol (I3C) and myo-inositol (MI) inhibit lung adenoma induced by tobacco smoke carcinogens in A/J mice.
  • In this paper, we extended our work and examined the effects of I3C (70 or 30 micromol/g diet) and MI (56 micromol/g diet) against vinyl carbamate (VC)-induced lung adenocarcinoma by administering the agents from 1 week after the second of two injections of VC until termination of the study at week 18.
  • The higher dose of I3C decreased multiplicities of tumors on the surface of the lung (26%, P = 0.0005), carcinoma incidence (38%), multiplicity (67%, P < 0.0001) and size (complete abolition of carcinoma with an area of >1.0 cm(2)) as well as adenoma with cellular pleomorphism (46%, P < 0.0001).
  • MI decreased multiplicities of pulmonary surface tumors (20%, P = 0.0005), adenoma with cellular pleomorphism (40%, P < 0.0001) and lung adenoma (52%, P < 0.0001) and the proportion of the biggest carcinoma (carcinoma with an area of >1.0 cm(2), P < 0.05).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6853-66 [10602461.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5592-600 [19531648.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):757-72 [11195469.001]
  • [Cites] Cancer Lett. 2001 Jun 10;167(1):1-6 [11323092.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2927-36 [11420705.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):642-6 [11830512.001]
  • [Cites] Carcinogenesis. 2002 Sep;23(9):1455-61 [12189187.001]
  • [Cites] Chest. 2003 Nov;124(5):1828-33 [14605056.001]
  • [Cites] Carcinogenesis. 2004 Feb;25(2):197-201 [14578161.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):45-52 [15179623.001]
  • [Cites] Nutr Cancer. 2004;48(1):84-94 [15203382.001]
  • [Cites] Prostate. 2004 Oct 1;61(2):153-60 [15305338.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2613-7 [2328487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9543-7 [1658785.001]
  • [Cites] Carcinogenesis. 1993 Sep;14(9):1975-7 [8403228.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5132-5 [8912846.001]
  • [Cites] Anticancer Res. 1996 Sep-Oct;16(5A):2709-12 [8917375.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):139-45 [9934861.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2053-9 [15240509.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:236-43 [15574364.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1137-41 [15797040.001]
  • [Cites] Blood. 2005 Jul 15;106(2):641-9 [15811958.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8548-57 [16166336.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):541-50 [16199440.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):717-28 [16332727.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4952-60 [16651453.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1526-31 [16896044.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2116-23 [16704990.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2747-56 [17121921.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11494-501 [17145898.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6502-11 [17616712.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2757-65 [17913854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7139-45 [18056164.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2458-64 [18413838.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Sep;1(4):285-97 [19138972.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Dec;1(7):568-76 [19139007.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 1;101(7):519-32 [19318631.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):370-6 [19336734.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5764-71 [11126363.001]
  • (PMID = 19625346.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-102502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Indoles; 12001-76-2 / Vitamin B Complex; 3IN71E75Z5 / Urethane; 4L6452S749 / Inositol; 7Y2431GOM5 / vinyl carbamate; C11E72455F / indole-3-carbinol; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2812566
  •  go-up   go-down


97. Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson BC, Lockwood G, Gallinger S, Egan SE: Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol; 2008 Dec;33(6):1223-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of Notch signaling in human colon adenocarcinoma.
  • Studies in mice have also shown that Notch signaling is required for adenoma formation in response to elevated Wnt-pathway signaling that occurs in the APCMin mouse model of human adenomatous polyposis coli.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2008 Jan;134(1):131-44 [18166351.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11128-32 [18056436.001]
  • [Cites] Cell Oncol. 2008;30(1):1-11 [18219106.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2155-8 [11739954.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):36-44 [10615124.001]
  • [Cites] EMBO Rep. 2008 Apr;9(4):377-83 [18274550.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1095-7 [11884509.001]
  • [Cites] Cell. 2002 Oct 18;111(2):251-63 [12408869.001]
  • [Cites] Gene Expr Patterns. 2002 Dec;2(3-4):247-50 [12617809.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Oct;4(10):786-97 [14570055.001]
  • [Cites] J Histochem Cytochem. 2004 Apr;52(4):509-16 [15034002.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):145-63 [15300010.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6050-7 [15342386.001]
  • [Cites] Development. 1997 Jun;124(11):2245-54 [9187150.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):283-8 [9207795.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1998 Jun 29;353(1370):915-23 [9684289.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Development. 2005 Mar;132(5):1093-104 [15689380.001]
  • [Cites] Genes Dev. 2005 Apr 15;19(8):877-90 [15833914.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):964-8 [15959516.001]
  • [Cites] Nature. 2005 Jun 23;435(7045):1126-30 [15973414.001]
  • [Cites] Genes Dev. 2005 Jul 15;19(14):1686-91 [16024658.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12443-8 [16107537.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8530-7 [16166334.001]
  • [Cites] Trends Mol Med. 2005 Nov;11(11):496-502 [16214417.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1059:174-83 [16382053.001]
  • [Cites] Dev Dyn. 2006 Sep;235(9):2330-6 [16724326.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2437-47 [16888285.001]
  • [Cites] Development. 2007 Feb;134(3):535-44 [17215306.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):685-93 [17507991.001]
  • [Cites] Development. 2007 Aug;134(15):2709-18 [17611219.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15418-23 [17881565.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2331-43 [17982118.001]
  • [Cites] Development. 2008 Feb;135(3):411-24 [18192283.001]
  • (PMID = 19020755.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA074783; United States / NCI NIH HHS / CA / RFA#CA-96-011; United States / NCI NIH HHS / CA / U01 CA074783-06; United States / NCI NIH HHS / CA / CA074783-06; United States / NCI NIH HHS / CA / CA074783-05; United States / NCI NIH HHS / CA / U01 CA074783-05; United States / NCI NIH HHS / CA / U01 CA074783
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Calcium-Binding Proteins; 0 / Homeodomain Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / NOTCH1 protein, human; 0 / RNA, Messenger; 0 / Receptor, Notch1; 0 / Receptors, Notch; 134324-36-0 / Serrate proteins; 149348-15-2 / HES1 protein, human; EC 2.4.- / Glycosyltransferases; EC 2.4.1.- / LFNG protein, human
  • [Other-IDs] NLM/ NIHMS139694; NLM/ PMC2739737
  •  go-up   go-down


98. Cheung WL, Cao D: Colonic-type adenocarcinoma arising in a primary retroperitoneal mature cystic teratoma. Pathol Int; 2008 Dec;58(12):792-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic-type adenocarcinoma arising in a primary retroperitoneal mature cystic teratoma.
  • Pathology indicated a colonic-type adenocarcinoma arising in a primary retroperitoneal mature cystic teratoma.
  • The adenocarcinoma was predominantly intracystic with focal superficial invasion into the cyst wall but not beyond the teratoma capsule.
  • Immunohistochemistry showed that the adenocarcinoma cells were diffusely positive for cytokeratin 20 (CK20) and caudal-type homeobox transcription factor-2 (CDX2) but negative for CK7, confirming the colonic phenotype.
  • In addition, the adenocarcinoma was seen adjacent to teratomatous colonic-type mucosa with adenomatous change (i.e. adenoma), suggesting that it was probably arising from a colonic-type adenoma within the teratoma.
  • To the authors' knowledge this is the first documented case in which a colonic-type adenocarcinoma was seen arising from a precursor lesion (i.e. a colonic-type adenoma in a primary retroperitoneal mature cystic teratoma) and is the second case of intestinal-type adenocarcinoma arising in a primary retroperitoneal mature cystic teratoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067855.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Ki-67 Antigen
  •  go-up   go-down


99. Hartmann A, Junker K, Dietmaier W, Schröder S, Lopez D, Hofstädter F, Blaszyk H: Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma. Hum Pathol; 2006 Jan;37(1):117-20
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma.
  • Nephrogenic metaplasia or nephrogenic adenoma of the urinary tract may present a diagnostic challenge in surgical pathology practice.
  • Previous case reports suggest the possibility of nephrogenic metaplasia progressing to clear cell adenocarcinoma, but a malignant potential of nephrogenic metaplasia is generally not acknowledged.
  • A case of a 70-year-old female patient with multiple recurrences of nephrogenic metaplasia of the urinary bladder and subsequent development of clear cell adenocarcinoma is described.
  • Results of molecular studies, particularly comparative genomic hybridization analysis, suggest clonal evolution of nephrogenic metaplasia to clear cell adenocarcinoma in this case.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Precancerous Conditions / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360424.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


100. Piana S, Asioli S, Foroni M: Oncocytic adenocarcinoma of the rectum arising on a villous adenoma with oncocytic features. Virchows Arch; 2006 Feb;448(2):228-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic adenocarcinoma of the rectum arising on a villous adenoma with oncocytic features.
  • Rectal adenocarcinoma with diffuse oncocytic features is a very rare lesion, having been reported only once in the English literature.
  • We describe a case of oncocytic adenocarcinoma of the rectum, associated with a villous adenoma, arising on a 66-year-old man.
  • On histological examination, the adenocarcinoma was composed of neoplastic glands lined by a strongly eosinophilic, granular epithelium that deeply infiltrated the rectal wall.
  • Superficially, a villous adenoma with high-grade dysplasia was evident; adenomatous cells showed focal eosinophilic changes, consisting of a large granular cytoplasm, an oval atypical nucleus, and a prominent nucleolus.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Aug;30(8):926-33 [10452505.001]
  • [Cites] Cell. 1993 Aug 27;74(4):597-608 [8358789.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):98-104 [10452575.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] Virchows Arch. 2000 Jun;436(6):602-7 [10917176.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):29-35 [15735852.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Pathol Oncol Res. 1999;5(4):273-9 [10607921.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] J Clin Pathol. 1995 Jan;48(1):46-52 [7706518.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1071-6 [8892593.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):579-82 [12955503.001]
  • [Cites] J Pathol. 1994 Apr;172(4):337-42 [8207614.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):458-65 [11914623.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1054-64 [7522412.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):146-61 [10452580.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):102-10 [8617450.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:452-83 [13904234.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):126-34 [10452578.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):696-700 [2661411.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Virchows Arch. 1997 Feb;430(2):125-30 [9083515.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):117-25 [10452577.001]
  • [Cites] J Pathol. 1993 Apr;169(4):431-7 [8501540.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):135-45 [10452579.001]
  • (PMID = 16450120.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down






Advertisement